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How MANY TIMES DoI HAVE TO TELL You?!: EPA's
ONGOING STRUGGLE WITH DATA FROM THIRD- PARTY
PESTICIDE TOXICITY STUDIES USING HUMAN SUBJECrs
HEIDI GOROVITZ ROBERTSON'
I. INTRODUCTION
The United States Environmental Protection Agency ("EPA") is attemp-
ting to address a problem it has seen and grappled with before. Specifically,
the Agency is attempting to decide whether and how it should evaluate and
use data from third-party pesticide toxicity studies involving human subjects.
EPA is particularly interested in this problem as it applies to regulatory
decisions regarding human exposure to pesticides. Third party studies using
human subjects are of particular concern because, although human-based
studies performed or funded by a federal government agency are subject to
the Common Rule for the Protection of Human Subjects ("Common Rule"),'
"Associate Professor of Law, Cleveland-Marshall College of Law, and Associate Professor
of Environmental Studies, Maxine Goodman Levin College of Urban Affairs, Cleveland
State University. Special thanks to my father, Samuel Gorovitz, who was my co-author on
a related article, for inspiring me to think and write about these issues. Thanks also to my
research assistants, Jamie Ginsberg, for his hard work and stellar research skills, and David
Smith, for helping out in our hour of need.
Federal Policy for the Protection of Human Subjects, 56 Fed. Reg. 28,001 (June 18, 1991)
(codified at scattered sections of the C.F.R.); accord 40 C.F.R. §§ 26.01-.124 (2003)
(codifying EPA's implementation of the Common Rule). A total of fifteen agencies have
adopted the Common Rule, which is the set of federal regulations governing research
involving human participants. Federal Policy for the Protection of Human Subjects, 56 Fed.
Reg. at 28,004. The Common Rule "applies to all research involving human subjects
conducted, supported or otherwise subject to regulation by any Federal department or
agency." 40 C.F.R. § 26.101(a) (2003). The Common Rule requires that federally funded
research receive review and approval from an institutional review board ("IRB"). 40 C.F.R.
§ 26.103(0 (2003). The IRB must include at least five members with varying backgrounds,
such that the group can completely and adequately review the research activities commonly
conducted by the institution. 40 C.F.R. § 26.107(a) (2003). The IRB must review the
research design to determine whether it follows sound procedures that minimize the risks to
which subjects are exposed, to evaluate the anticipated benefits of the research compared to
the risks it poses to the subjects, to determine whether the study's choice of research subjects
is appropriate, to ensure that researchers have provided informed consent accurately and with
proper documentation, and to verify that the study will protect the safety and privacy of the
subjects. 40 C.F.R. § 26.111 (a) (2003). With respect to informed consent, the Common Rule
require- that the researcher provide:
(1) A statement that the study involves research, an explanation of the
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purposes of the research and the expected duration of the subject's
participation, a description of the procedures to be followed, and
identification of any procedures which are experimental;
(2) A description of any reasonably foreseeable risks or discomforts to
the subject;
(3) A description of any benefits to the subject . . .which may
reasonably be expected from the research;
(4) A disclosure of appropriate alternative procedures or courses of
treatment, if any, that might be advantageous to the subject;
(5) A statement describing the extent, if any, to which confidentiality of
records... will be maintained;
(6) For research involving more than minimal risk, an explanation as to
whether any compensation and an explanation as to whether any
medical treatments are available if injury occurs...
(7) An explanation of whom to contact for answers to pertinent
questions about [the] research and the subject's rights, and whom to
contact in the event of a research-related injury ... and ... [a]
statement that participation is voluntary, refusal to participate will
involve no penalty or loss of benefits to which the subject is
otherwise entitled, and the subject may discontinue participation at
any time ....
40 C.F.R. § 26.116(a)(l)-(8) (2003). The Common Rule provides additional elements of
informed consent as appropriate under the circumstances of the research. See id. § 26.116(b).
Governmental officials may not approve research without IRB approval. 40 C.F.R. §
26.112 (2003). Additionally, the IRB has the power "to suspend or terminate" research
causing "unexpected serious harm to subjects" or research violating IRB requirements. 40
C.F.R. § 26.113 (2003). The Common Rule began its evolution in 1981 after the President's
Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral
Research suggested that all federal agencies follow a single policy to determine the ethics of
research involving human subjects. See PRESIDENT'S COMM'N FOR THE STUDY OF ETHICAL
PROBLEMS IN MED. & BIOMED. & BEHAVIORAL RESEARCH, PROTECTING HUMAN SUBJECTS:
FIRST BIENNIAL REPORT ON THE ADEQUACY AND UNIFORMITY OF FEDERAL RULES AND
POLICIES, AND THEIR IMPLEMENTATION FOR THE PROTECTION OF HUMAN SUBJECTS IN
BIOMEDICAL AND BEHAVIORAL RESEARCH 12, 67-73 (U.S. Gov't Printing Office 1981)
[hereinafter PRESIDENT'S COMM'N]. This commission suggested that agencies needed
guidance and consistency regarding how they should determine what types ofhuman research
to allow and what standards that research should meet. Id. By June 18, 1991, the Office for
Protection from Research Risks ("OPRR") had organized the sixteen agencies and
departments that ratified the model policy to agree to simultaneously publish the Common
Rule. Federal Policy for the Protection of Human Subjects, 56 Fed. Reg. at 28,003. At the
time, each agency wanted specific exemptions. Charles R. McCarthy, Reflections on the
Organizational Locus of the Office for Protection from Research Risks, in 2 ETHICAL AND
POLICY ISSUES IN RESEARCH INVOLVING HUMAN PARTICIPANTS H- 1, H- 16 (Nat'l Bioethics
Advisory Review Comm'n 2001). For example, "[t]he Department of Agriculture and the
Environmental Protection Agency sought exceptions for pesticide research and food testing
research." Id. at H-17. The OPRR managed to get the agencies to drop their exemption
requests with the help of the Office of Management and Budget and the Office of Science and
Technology Policy. Id. The Common Rule "remains the only successful 'cross-cutting'
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privately funded studies are not subject to the same federally-mandated
precautions. These precautions require, among other things, that Common
Rule studies be pre-approved by an Institutional Review Board, that the re-
search subjects consent voluntarily to their participation after being informed
about the risks and benefits of the study, and that risks to participants be mi-
nimized.3 EPA has long had no formal policy regarding how it should view
data from pesticide toxicity studies involving human subjects where those
studies were not covered by the Common Rule.
If EPA accepts data from non-Common Rule studies and uses them in
making decisions on pesticide registration, labeling, and other toxicity and
exposure related issues, then EPA effectively encourages pesticide manufac-
turers to conduct human studies and submit the resulting data to the Agency.
Some argue that if EPA refuses to accept data from such studies, the Agency
would bar useful information regarding pesticide toxicity from its decision-
making processes. EPA sought and received much advice on the subject. It
heard from, among others, the President's Commission for the Study of Ethi-
cal Problems in Medicine and Biomedical and Behavioral Research, the Na-
tional Bioethics Advisory Commission, and a joint subcommittee of EPA's
Science Advisory Board ("SAB") and FIFRA Scientific Advisory Panel
("SAP"). The advice these commissions and advisory panels have given to
the Agency is largely consistent. The panels and commissions voice concerns
about the ethics of intentionally dosing human beings with pesticides, espe-
cially for the purpose of encouraging EPA to set lower standards and allow
more abundant use of pesticides.
Despite having this question answered for it by several expert panels,
EPA has asked repeatedly for more advice, and different experts, and still has
not adopted a policy. The most recent iteration of these requests places the
problem in the hands of the National Academy of Sciences ("NAS"), from
(across all federal departments and agencies) [rule] in the federal government." Id. at H-28
n.25.
2 Although they are not subject to the Common Rule, studies conducted by third parties are
subject to a provision in the Federal Insecticide, Fungicide, and Rodenticide Act ("FIFRA"),
7 U.S.C. §§ 136-136y (2000), that forbids using a pesticide in research on human subjects
unless the participants are fully informed and voluntarily consent to participate in the study.
7 U.S.C. § 136j(a)(2)(p) (2000). EPA has taken enforcement action when it has discovered
violations of this provision. William Jordan, Remarks at Meeting of the National Human
Research Protections Advisory Committee 172-73 (Apr. 29, 2002), transcript available at
http://ohrp.osophs.dhhs.gov/nhrpac/mtg04-02/mtg0402.htr.
'See 7 U.S.C. § 136j(a)(2)(P) (2000).
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which EPA expected a report in December 2003.' In addition, in July 2003,
EPA requested nominations for experts for a new ad hoc committee of its
Science Advisory Board's Bioethics Advisory Committee.5 According to
EPA, this new committee, once formed and operational, will provide advice
to EPA on ethical issues concerning the generation and use of human and
animal data.6 In addition, EPA published in the Federal Register, an Advance
Notice of Proposed Rulemaking indicating that it will embark on a rule-
making process on the use of data from third-party pesticide toxicity studies
using human subjects.7
This Article will set forth the genesis of this problem by explaining how
EPA determines safe exposure levels for pesticides and describing the
evolving role human subject research has played in that process since the
passage of the Food Quality Protection Act of 1996 ("FQPA").8 It will then
describe the voluminous information EPA has received through its own and
other studies of the problem of data from third-party pesticide toxicity studies
using human subjects. Finally, this Article will set forth several existing
guidelines EPA might follow as it attempts to establish a formal policy
regarding the use of data from non-Common Rule human studies in decisions
regarding human exposure to pesticides.
4 As of the publication deadline of this article, NAS has not released a report or draft report
on the subject. NAS advised that the report is now due out Spring 2004. E-mail from
Rhashida Beynum, Pub. Access Records Office, to Todd Muldrew, Envt'l L & Pol'y Rev.
Articles Editor (Jan. 13, 2004) (on file with Envt'l L. & Pol'y Rev.).
I Science Advisory Board, Request for Nominations, Bioethics Advisory Committee (BAC),
an ad hoc committee of the U.S. EPA Science Advisory Board, 68 Fed. Reg. 41,128, 41,128-
30 (July 10, 2003).
6 Id. at 41,129. Nominations for this latest committee were due on July 31, 2003. Id. at
41,128. As of September 2, 2003, however, nominations were still being accepted, and anew
EPA officer, Designated Federal Officer, EPA Science Advisory Board Staff, Dr. Suhair
Shallal, was placed in charge of the committee formation. E-mail from Tom Miller,
Designated Fed. Officer, Envtl. Prot. Agency Science Advisory Bd., to Heidi Gorovitz
Robertson (Sept. 2, 2003) (on file with author). SAB hopes to have this committee formed
by late January 2004. E-mail from Dr. Suhair Shallal to Heidi Gorovitz Robertson (Nov. 24,
2003) (on file with author).
' Human Testing; Advance Notice of Proposed Rulemaking, 68 Fed. Reg. 24,410, 24,413
Proposed May 7, 2003) (to be codified 40 C.F.R. pt. 1).
7 U.S.C. §§ 136-136y (2000).
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II. BACKGROUND
A. The Food Quality Protection Act of 1996 and EPA's Risk Assessment
Process: Why Human Subjects Research Matters to the Pesticide
Industry
Within the realm of pesticides, the issue of how to view data from non-
Common Rule human studies arose with some urgency following the passage
of the FQPA. The FQPA requires EPA to reassess, for 9,721 pesticides, the
allowable amounts, or tolerances, of those pesticides that can remain on food
without the food being declared adulterated.9 EPA must complete this enor-
mous task by 2006.0 Most significant for pesticide manufacturers, FQPA
requires EPA to apply to its risk assessment method" for setting tolerances,
" 21 U.S.C. § 346a(q)(1) (2000); see also OFFICE OF PESTICIDE PROGRAMS, ENVTL. PROT.
AGENCY, FY 2001 REPORT: PARTNERS AND STAKEHOLDERS: WORKING TOGETHER TO
PROTECT HEALTH AND THE ENVIRONMENT 4 fig. (2002) ("By August 2006, EPA must
complete the review of all [9,721 ] tolerances that were in effect in August 1996 when FQPA
was passed."), available at http://www.epa.gov/oppfeadl/annual/2001/2001annual.pdf
[hereinafter OPP FY 2001 REPORT]. EPA must complete reassessment of thirty-three percent
of these tolerances by August 1999, sixty-six percent by August 2002, and the remaining
tolerances by August 2006. 21 U.S.C. § 346a(q)(1). See generally OFFICE OF PESTICIDE
PROGRAMS, ENVTL. PROT. AGENCY, Doc. No. 735-R-99001, IMPLEMENTING THE FOOD
QUALITY PROTECTION ACT 11-12 (1999) ("As required by FQPA, [EPA] reassessed 3290
tolerances by July 30, 1999, surpassing the 33% goal for August 1999 .... Among the
reassessed tolerances are 1493 tolerance revocations, of which 1258 are for pesticides in
priority Group 1, and 796 are for organophosphates, carbamates, organochlorines, and
carcinogens."), available at http://www.epa.gov/oppfeadl/fqpa/fqpareport.pdf [hereinafter
IMPLEMENTING FQPA]; OPP FY 2001 REPORT, supra, at 4 fig. (reporting that as of
September 2001, EPA had completed the reassessment of 3,832 tolerances); ENVTL. PROT.
AGENCY, STAFF BACKGROUND PAPER FOR NOVEMBER 30,1999 MEETING OF SAB/SAP JOINT
SUBCOMMITTEE ON DATA FROM HUMAN SUBJECTS (1999) (describing legal and policy
concerns to be taken into consideration in this meeting), available at http://www.epa.gov/
scipoly/sap/1999/november/background-I 130.pdf [hereinafter STAFF BACKGROUNDPAPER].
10 21 U.S.C. § 346a(q)(1) (2000).
" Risk assessment is a set of methods EPA and others use to evaluate the risk associated with
a particular action. In the case of pesticide risk assessment, EPA begins with hazard
identification, determining the toxicological effects or endpoints, of a pesticide. ENVTL.
PROT. AGENCY, TRAC STAFF PAPER NO. 44, EPA'S RISK ASSESSMENT PROCESS FOR
TOLERANCE REASSESSMENT 4 (1999), available at http://www.epa.gov/oppfeadl/trac/
paper44.pdf [hereinafter TRAC STAFF PAPER No.44]. The next step is a dose response
assessment, determining the highest level ofexposure at which there is no observable adverse
effect ("NOAEL"). Id. at 4-5. Third, EPA performs an exposure assessment, attempting to
determine the amount and circumstances of likely human exposure to the pesticide. Id. at 6.
Finally, in the risk characterization stage of the risk assessment, EPA attempts to characterize
the magnitude of the risk by "combining hazard, dose-response, and exposure information."
Id. at 10.
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an additional tenfold safety factor to increase safety for infants and children. 2
FQPA requires EPA to apply this additional tenfold safety factor to its toler-
ances unless reliable data support the use of a different factor. 3
EPA first determines the "No-Observed-Adverse-Effect-Level"
("NOAEL"). 4 EPA does this by examining the results of tests, usually done
on laboratory animals, to determine the highest dose at which there were no
observable adverse effects.'" EPA then calculates a reference dose ("RID")
for a particular pesticide.' 6 The RID is the amount of a pesticide a person
could consume daily, for seventy years, with no harmful, non-cancerous,
effect. 7 To determine the RfD, EPA divides the NOAEL by a series of"un-
certainty factors."' 8 These uncertainty factors apply in quantitative risk
assessments under circumstances where actual quantitative information is not
available. 9 For example, when the applicable study is an animal study, there
2 Pesticides: Determination of the Appropriate FQPA Safety Factor(s) in Tolerance
Assessment, 67 Fed. Reg. 9,271,9,272 (Feb. 28, 2002) (explaining that the additional tenfold
factor is to "tak[e] into account the potential for pre- and postnatal toxicity and the
completeness of the toxicology and exposure databases" that OPP uses in the risk assessment
process); OFFICE OF PESTICIDE PROGRAM, ENVTL. PROT. AGENCY, DETERMINATION OF THE
APPROPRIATE FQPA SAFETY FACTOR(S) rN TOLERANCE ASSESSMENT 4 (May 28, 2002),
available at http://www.epa.gov/oppfeadl/trac/science/determ.pdf [hereinafter DETER-
MINATION OF THE APPROPRIATE FQPA SAFETY FACTOR(S)]
3 FQPA establishes a new safety standard and new procedures for EPA's pesticide tolerance-
setting activities. EPA can establish, revise, or leave in effect a tolerance only if it is
determined to be "safe." 21 U.S.C. § 346a(b)(2)(A)(i) (2000). A determination that a
tolerance is "safe" means that "there is a reasonable certainty that no harm will result from
aggregate exposure to the pesticide chemical residue, including all anticipated dietary
exposures and all other exposures for which there is reliable information." Id. at §
346a(b)(2)(A)(ii). EPA must give special consideration to infants and children by ensuring
"that there is a reasonable certainty that no harm will result to infants and children from
aggregate exposure to the pesticide chemical residue." Id. at § 346a(b)(2)(C)(ii)(I).
FQPA instructs EPA, in making its "reasonable certainty of no harm" finding, that
in the case of threshold effects.... an additional tenfold margin of safety
for the pesticide chemical residue and other sources of exposure shall be
applied for infants and children to take into account potential pre- and
postnatal toxicity and completeness of the data with respect to exposure
and toxicity to infants and children. ... [T]he Administrator may use a
different margin of safety for the pesticide chemical residue only if, on the
basis of reliable data, such margin will be safe for infants and children.
Id. at § 346a(b)(2)(C). Compare Pesticides; Determination of the Appropriate FQPA Safety
Factor(s) in Tolerance Assessment, 67 Fed. Reg. at 9,272-73.
14 TRAC STAFF PAPER NO. 44, supra note 11, at 5.
1S Id.
16 id.17 id.
18/d.
19Id.
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is no actual quantitative information available regarding the effect the
pesticide would have on humans.20 So, EPA applies a tenfold "interspecies
uncertainty factor" to compensate for the uncertainty that exists when using
animal studies to determine safe doses for humans. 2' According to EPA, the
uncertainty factors are intentionally conservative, and are designed to reduce
risk when the Agency is making decisions in a quantitative vacuum.2
When EPA determines a RfD using results from the endpoint of a
human study, it need not apply the tenfold interspecies uncertainty factor.23
In that instance, EPA is starting from a different, perhaps higher, number
when it applies the additional tenfold safety factor required by FQPA. 4
Pesticide manufacturers cannot avoid FQPA's additional tenfold safety factor
for the protection ofhuman infants and children.25 If they can provide reliable
human data, however, they could conceivably avoid or reduce the interspecies
uncertainty factor. Therefore, pesticide manufacturers have been testing
pesticides directly on human subjects in efforts to avoid or reduce the
interspecies factor required following animal tests.2 6 Specifically, manu-
facturers have conducted pesticide toxicity studies in which human subjects
are dosed intentionally with pesticide-laced tablets, in a laboratory setting, to
evaluate at what level of exposure the pesticide will elicit an adverse re-
sponse.2 7 By using human studies to determine a NOAEL, researchers
provide EPA with endpoint data to which the Agency can apply the FQPA
additional safety factor, without application of an interspecies uncertainty
factor, when setting a tolerance.28
20 TRAC STAFF PAPER NO.44, supra note 11, at 5.
2! Id.; DETERMINATION OF THE APPROPRIATE FQPA SAFETY FACTOR(S), supra note 12, at 9
fig.1.
22 See DETERMINATION OF THE APPROPRIATE FQPA SAFETY FACTOR(S), supra note 12, at 51.
23 STAFF BACKGROUND PAPER, supra note 9, at 2.
24 Id.
25 SCI. ADVISORY BD. & THE FIFRA SCIENTIFIC ADVISORY PANEL, ENVTL. PROT. AGENCY,
EPA-SAB-EC-00-017, COMMENTS ON THE USE OF DATA FROM THE TESTING OF HUMAN
SUBJECTS 3 (2000), available at http://www.epa.gov/sciencel/pdf/ec0017.pdf [hereinafter
SAB & FIFRA SAP].
26 Jordan, supra note 2, at 173.
27 Id. at 172.
28 See SAB & FIFRA SAP, supra note 25, at 5. Because no one asserts that it is ethical to
perform intentional dose toxicity studies on human children, it is unlikely that the industry
will be able to provide reliable data on a pesticide's effect on children. Id. at 15. Therefore,
EPA will continue to apply the FQPA additional safety factor to the NOAEL it determines
based on either adult human or animal-based research. See id. at 5.
2004]
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According to EPA, "[i]t is unusual for the actual numerical value of the
NOAEL to be identical in human and animal studies, but using human data
generally tends to raise the 'safe dose,' even as the additional FQPA [safety]
factor works to lower it."29 Higher safe doses mean more pesticides will be
allowed on foods. Lower safe doses lead to reductions in the permitted uses
of a pesticide.3°Therefore, pesticide manufacturers seek to reduce the
29 STAFF BACKGROUND PAPER, supra note 9, at para. 12.
30
Five uncertainty factors and one modifying factor have been
identified for application to the NOAEL or BMD [Benchmark Dose] to
derive hazard values such as the acute or chronic reference dose (RID).
These include the following:
1) the interspecies uncertainty factor which is intended to account for
the uncertainty involved in extrapolating from animal data to
humans;
2) the intraspecies uncertainty factor which is intended to account for
the variation in sensitivity among the members of the human
population including children;
3) an uncertainty factor to extrapolate from subchronic to chronic data,
if deriving a chronic RfD;
4) an uncertainty factor to extrapolate from the LOAEL [Lowest-
Observed-Adverse-Effect-Level] to the NOAEL, if no appropriate
NOAEL can be identified in the toxicology database, and
5) an uncertainty factor to account for the absence of key data sets in
the database for a given chemical.
An additional modifying factor may also be applied when scientific
uncertainties in the study chosen for derivation of the RID exist or when
other aspects of the database are not explicitly addressed by one or more
of the five uncertainty factors (e.g., statistically minimal group sample size
or poor exposure characterization). The maximum default value for each
of the five uncertainty factors and the modifying factor is 10, although
sometimes a different factor (often 3X) is used, depending on the nature
and quality of the information available on the pesticide. The composite
uncertainty/modifying factor is never to exceed 10,000, and, in practice,
rarely exceeds 1000, particularly for pesticides.
The intraspecies uncertainty factor and the database uncertainty
factor are especially relevant to protecting children's health, in the context
of implementation of FQPA and the application of FQPA Safety Factor.
The intraspecies uncertainty factor is applied to account for variations in
susceptibility within the human population (including children) (emphasis
omitted).
OFFICE OF PESTICIDE PROGRAMS, ENVTL. PROT. AGENCY, THE OFFICE OF PESTICIDE
PROGRAMS' POLICY ON DETERMINATION OF THE APPROPRIATE FQPA SAFETY FACTOR(S) FOR
USE IN THE TOLERANCE-SETTING PROCESS 25-26 (1999) (draft), available at http://www.epa.
gov/scipoly/sap/1999/may/10xpoli.pdf [hereinafter OPP DRAFT POLICY]; accord DETER-
MINATION OF THE APPROPRIATE FQPA SAFETY FACTORS, supra note 12 (final version of draft
documents). See generally Dourson et al., Evolution of Science-Based Uncertainty Factors
in Noncancer Risk Assessment, 24 REG. TOXICOLOGY & PHAR-MACOLOGY 108 (1996)
(evaluating uncertainty factors using data from animals or human studies).
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uncertainty multipliers that EPA will use in its risk assessments by providing
reliable supporting data from human subjects.
Pesticide manufacturers have long sought to provide EPA with data to
review as it makes decisions regarding pesticide registration, labeling, or
other forms of regulation.3' In the past, EPA has encouraged some kinds of
research with human subjects, specifically research concerning the potential
for some pesticides to irritate or sensitize human skin, or testing of the
metabolic rates of pesticides in the human system.32 Most of this research
derived from the monitoring of agricultural workers exposed to pesticides in
the course of their employment. 33 Between 1986 and 1996, third parties
submitted very few human tests to EPA. According to EPA, as of April 29,
2002, human studies represented less than one percent of the total studies
submitted to the Agency in a year.34
In addition to these tests involving the monitoring of agricultural
workers, which EPA has encouraged, third parties have voluntarily submitted
to EPA studies involving human subjects intentionally exposed to pesticides,
either through ingestion, inhalation, or dermal contact, in a laboratory
setting.35 The studies that are of specific concern are those that involve the
intentional dosing of human subjects with pesticides for the purpose of
establishing a NOAEL, or No Observed Effect Level ("NOEL"), for systemic
toxicity of certain pesticides to humans.36 Before Congress' passage of
FQPA, the number of human studies that involved intentionally dosing
31 At the initial SAP/SAB subcommittee meeting in December 1998, EPA representatives
presented information on the Agency's acceptance of human studies between Jan 1, 1990 and
August 31, 1998. During that period, industry submitted twenty-six human effects studies
based on "intentional clinical exposure . . . ." The studies addressed metabolism,
pharmacokinetics, and other effects. Eight studies dealt with toxicity and NOAEL. Briefing
Paper, Ctr. for Regulatory Effectiveness, EPA's Policy for Acceptability of Human Volunteer
Test Data, Prior EPA Policy and Practice in Accepting Human Volunteer Studies of
Pesticides (June 8, 2000), available at http://www.thecre.com/special-projects/human/
volunteer/hvtd/hvtd.html; see also Pat Phibbs, Bill Would Subject Pesticide Research, Other
Studies to Federal Ethics Standards, [92] Daily Env't. Rep. (BNA) A-3, A-4 (May 13,
2002).
32 Human Testing; Advance Notice of Proposed Rulemaking, 68 Fed. Reg. 24,410, 24,413
roposed May 7, 2003) (to be codified at 40 C.F.R. pt.1).
Id.
14 Jordan, supra note 2, at 172.
" Human Testing, 68 Fed. Reg. at 24,413.36 Id.
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humans to establish toxicity was usually less than half a percent.37 EPA did
rely on some of these studies to support regulatory decisions prior to 1996.38
Even understanding the low percentage of total human data submitted
to the Agency that these intentional dosing studies represent, Congress'
passage of FQPA increased the raw number of such studies submitted to
EPA.3 9 From the passage of FQPA in 1996, through November 30, 1999,
pesticide manufacturers and chemical companies submitted data to EPA from
fourteen studies that used human subjects to determine a NOAEL or NOEL
for systemic toxicity of pesticides.' ° Since EPA initiated a moratorium on
human dosing studies in March 2001, third parties submitted only two human
dosing studies, both of which commenced prior to the moratorium.4' EPA
stated on July 28, 1998, that it had not relied on any human dosing studies in
final decisions made under FQPA.42 In EPA's most recent Federal Register
notice on the subject,43 it stated that this remains true."
This decrease in the submission of human studies data came under
attack when pesticide industry lobbying groups sued EPA to challenge the
legality of its March 2001 moratorium in CropLife America v. EPA. 5 In
CropLife, the Court of Appeals for the D.C. Circuit struck down the
moratorium on the grounds that it amounted to a de facto regulation, which
EPA issued outside the requirements of the Administrative Procedure Act
("APA"). 6 Because the court struck down this moratorium, it is critical that
EPA evaluate the significant body of information available to it and adopt a
3 See Jordan, supra note 2, at 172.
a Human Testing, 68 Fed. Reg. at 24,413.
'9 STAFF BACKGROUND PAPER, supra note 9, at 2.40 See id. at 5-6 tbl. (listing fourteen human systemic NOAEL studies submitted to OPP since
passage of FQPA).
E-mail from William L. Jordan, Senior Policy Advisor, Envtl. Prot. Agency, to Heidi
Gorovitz Robertson (Mar. 24, 2003) (on file with author) (confirming third parties submitted
two studies in 2001).
42 Human Testing, 68 Fed. Reg. at 24,413.
43 See Human Testing, 68 Fed. Reg. 24,410 (announcing an Advance Notice of Proposed
Rulemaking on Human Testing).
44 Id. at 24,413.
45 329 F.3d 876 (D.C. Cir. 2003). CropLife America, other pesticide manufacturers, and a
trade association challenged the legality of EPA's decision not to consider human data from
third party pesticide toxicity studies which sought to establish a NOAEL. Id. at 878.
Previously, EPA accepted and reviewed intentional dosing of humans subject studies. Id. at
879. It did not use these studies, however, to approve pesticides or to establish NOAELs. Id.
at 880. In the oral arguments, CropLife contended that EPA rejected many intentional dosing
studies that used human subjects. Id. at 883.
4Id. at 884-85.
[Vol. 28:205214
How MANY TIMES Do I HAVE TO TELL YOU?!
policy that will provide the Agency with the toxicity information it needs,
while protecting all human research subjects, including those participating in
studies outside the scope of the Common Rule.47
B. The Common Rule and Institutional Review Boards
The Common Rule imposes standards for protecting human subjects of
research performed or supported by federal government agencies.4" Briefly
stated, the Common Rule applies to all research funded or regulated by
federal departments or agencies that have chosen to comply with this research
policy. 9 Even privately funded research that will need the approval of one of
these departments must comply with the Common Rule. 0 A particular de-
partment's director has the discretion to waive the Common Rule for research
in foreign countries, depending on the policy for protecting human subjects
of research in that country."' When the Common Rule applies, an Institutional
Review Board ("IRB") must approve proposed research on human subjects; 52
the risk to the human subjects must be both minimized (the amount of harm
in the research should not exceed that of an ordinary day)" and consistent
with sound research policy;5 4 the risk must be reasonable relative to the
benefits, if any, the subject will receive;5" and all human subjects must
provide informed consent that contains no exculpatory language releasing the
investigator from liability for negligence or waiver of any of the subject's
legal rights.5 6
47 The court vacated the EPA moratorium and reinstated EPA's prior case-by-case assessment
system which was based on the guidance of statutory requirements, the Common Rule, and
high ethical standards. CropLife, 329 F.3d at 879.
4 Protection of Human Subjects, 40 C.F.R. § 26.101 (2002); accord 7 C.F.R. § lc. l01
(2003) (Dep't of Agric.); 10 C.F.R. § 745.101 (2003) (Dep't of Energy); 14 C.F.R. §
1230.101 (2003) (NASA); 15 C.F.R. § 27.101 (Dep't of Commerce); 16 C.F.R. § 1028.101
(2002) (Consumer Prod. Safety Comm'n); 22 C.F.R. § 225.101 (2003) (Int'l Dev. Coop.
Agency & Agency for Int'l Dev.); 24 C.F.R. § 60.1 (2003) (Dep't of Hous. & Urban Dev.);
28 C.F.R. § 46.101 (2002) (Dep't of Justice); 32 C.F.R. § 219.101 (2003) (Dep't of
Defense); 34 C.F.R. § 97.101 (2002) (Dep't of Educ.); 38 C.F.R. § 16.101 (2003) (Dep't of
Veterans Affair); 45 C.F.R. § 49.101 (2003) (Dep't of Health & Human Serv.); 45 C.F.R.
9690.101 (2002) (Nat'l Sci. Found.); 49 C.F.R. § 11.101 (2002) (Dep't of Transp.).9 40 C.F.R. § 26.101; accord sources cited supra note 48.
o 40 C.F.R. § 26.102(e); accord sources cited supra note 48, at § x. 102(e).5140 C.F.R. § 26.101(h); accord sources cited supra note 48, at § x.101(h).
3240 C.F.R. § 26.103(b); accord sources cited supra note 48, at § x.103(b).
3 40 C.F.R. § 26.102(i); accord sources cited supra note 48, at § x.102(i).
'40 C.F.R. § 26.111 (a)(1); accord sources cited supra note 48, at § x. I I 1 (a)(1).
" 40 C.F.R. § 26.11 1(a)(2); accord sources cited supra note 48, at § x.l 1 1(a)(2).
56 40 C.F.R. § 26.116; accord sources cited supra note 48, at § x. 116.
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As stated above, the same standards do not apply when third parties,
such as pesticide manufacturers and chemical companies, conduct research
using human subjects, then submit their results to EPA in support of pesticide
registration applications. This is because EPA has not adopted the Common
Rule policies with respect to these types of studies.
C. History of Human Subjects Studies at EPA
Most of the human studies submitted to EPA since the passage of FQPA
in 1996 were conducted outside the United States.57 In 1999, however, Dow
AgriSciences ("Dow") conducted a study in Nebraska in which sixty human
subjects were paid to swallow tablets laced with the pesticide chlorpyrifos,
sold under the trade names Dursban or Lorsban.5 Half of the subjects got
placebos, and the other half ate chlorpyrifos-laced tablets. 9 Dow paid each
volunteer $460.' According to Dow, the pesticide-ingesting subjects ex-
hibited no signs of toxicity.6' EPA accepted and used this data in setting the
RfD for chlorpyrifos. 62 As a result, EPA did not need to apply the full inter-
" Pesticide Action Network N. Am., US. EPA to Allow Human Pesticide Tests, ACTION
NETWORK UPDATES SERVICE, Dec. 14, 2001, at para. 6, available at http://www.
panna.org/resources/panups/panup_20011214.dv.html [hereinafter PANNA].
" Id. In addition, in 1972, Dow hired doctors of Albany Medical College to feed Dursban
to inmates at the Clinton Correctional Institution in New York and record the results. Envtl.
Working Group, Dow UsedHumans as Experimental Guinea Pigs (on file with author). Such
studies are now illegal in the United States. Id.
59 Id.
60Id.
6 Id.; Elizabeth Shogren, U.S. Will Use Once-Banned Human Tests: Pesticides; EPA Says
It WillAccept Industry Data Gathered by Giving PaidSubjects Chemical Doses, L.A. TIMES,
Nov. 27, 2001, at Al (citing Garry Hamlin, spokesman for Dow Agrisciences, who said that
company's tests showed no signs of toxicity for the pesticide). But cf Joan Lowy, People
Used to Test Toxic Substances: Is It Right?, SCRIPPS HOWARD NEWS SERV., Jan. 3, 2003
(stating that study results showed that volunteers who ingested the pesticide suffered from
nausea, vomiting, abdominal pain, shortness of breath, impairment of sensation, and chest
pains), available at http://204.78.57.12/shns/gindex2.cfin?action=detail&pk=HUMAN
TESTING-01-03-03.
62 See, e.g., OFFICE OF PREVENTION, PESTICIDES & Toxic SUBSTANCES, ENVTL. PROT.
AGENCY, CASE No. (0100), INTERIM REREGISTRATION ELIGIBILITY DECISION FOR
CHLORPYRIFOS 16 (2001); see also John Heilprin, EPA Using Human Testing Data from
Manufacturers in Evaluating Pesticide Regulations, DODGE CITY DAILY GLOBE, Nov. 28,
2001, available athttp://dodgeglobe.com/stories/I 12801/natepa.shtml; Shogren, supra note
61, at A1; Shankar Vedantam, EPA Used Data from Human Pesticide Tests, WASH. POST,
Nov. 29, 2001, at A6. The EPA has used results from third-party human subject studies in
other instances, as well. See, e.g., OFFICE OF PREVENTION, PESTICIDES & TOXIC SUBSTANCES,
ENVTL. PROT. AGENCY, CASE NO. 0235, INTERIM REREGISTRATION ELIGIBILITY DECISION FOR
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species uncertainty factor.63 Despite the applicability of the FQPA tenfold
safety factor, the amount of this pesticide allowed on food is greater than it
would have been had the RfD been set using the endpoint of an animal study.
Because EPA accepted and used the data from this and other human studies,
the pesticide industry may be tempted to undertake similar, perhaps larger,
more dangerous, and less ethical tests. If this is so, EPA must have a credible
policy by which to evaluate and accept or reject the tests. 64
An additional example of this problem involves Cheminova Agro A/S
("Cheminova"), which manufactures several organophosphate insecticides.
Cheminova submitted to EPA a study of the insecticide malathion, in which
the lab conducting the study, Inveresk Research ("Inveresk"), administered
acute single-doses of the insecticide to human participants. 65 Although
Cheminova claims the study was conducted according to the highest ethical
standards,66 the study was not subject to the Common Rule because it was
privately funded by Cheminova and administered by Inveresk.
Other pesticide manufacturers have submitted similar studies on other
pesticides. 67 Those manufacturers would like to continue to submit, and have
EPA consider, data from these studies because that would allow EPA to find
lower NOAELs. With lower NOAELs, EPA could set more permissive RfDs
even while applying FQPA's required tenfold factor for the protection of
human infants and children. This would allow more pesticides of the
applicable type to be used, thus providing the pesticide manufacturers with
higher sales levels.68 In fact, the results of a single human study, if accepted
and used by EPA to set an RfD, could "make the difference of tens of
millions of dollars. ' 69 It is, in large part, because of the dollars at stake that
these tests became more popular with pesticide manufacturers since the
passage of FQPA.
Although pesticide manufacturers insist that they have complied with
the requirements of the Common Rule despite its inapplicability to their
AzINPHOS-METHYL 10-11 (2001).
63 See Shogren, supra note 61.
6 See, e.g., OPP DRAFT POLICY, supra note 30, at 25-26.
61 Cheminova Agro A/S, Comments at the Meeting of the Executive Committee of EPA
Scientific Advisory Committee on the May 31, 2000, Report by the Joint SAB/SAP
Subcommittee on Data from Testing of Human Subjects (June 16, 2000) (on file with the
author).
6 See id. at 1.
67 See id. at 1.
68 See id. at 1, 5.
69 PANNA, supra note 57, at para. 7.
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studies,70 EPA and others are concerned that the manufacturers' compliance,
because it is not required, may not be consistently and completely carried
out.7 Because the Common Rule does not apply to these studies, and EPA
has no internal policy or standards for them, pesticide manufacturers can
submit data to EPA from human-based studies without the research having
been approved by an IRB prior to its commencement. 72 This creates the
recurring dilemma regarding whether the Agency's use of this data in
decision-making condones its submission, thus perpetuating and encouraging
circumstances in which pesticide manufacturers conduct human testing
without seeking prior approval of an IRB.73
D. Some Pros and Cons of Human Subjects Research
Industry representatives argue that human testing allows pesticide
manufacturers to provide more accurate information regarding safe human
exposure thresholds.74 This type of research is commonly called "nonthera-
putic," or research that has no direct benefit to the subject.71
70 See Cheminova Agro A/S, supra note 65, at 1. But see Press Release, Natural Res. Def.
Council, EPA Reverses Ban on Testing Pesticides on Human Subjects (Nov. 28, 2001),
available at http://www.nrdc.org/media/pressReleases/0111 28a.asp (documenting the ways
in which a 1998 Bayer study of the effects of the insecticide azihphos methyl on human
subjects violated the Nuremberg Code, the Helsinki Declaration, FIFRA, the Common Rule,
and the recommendations of the EPA joint SAB and SAP subcommittee).
7' Cheminova Agro A/S, supra note 65, at 4.
7 2See generally SAB & FIFRA SAP, supra note 25, at 3 ("All research involving humans
should require prior review by an Institutional Review Board (IRB).").
The IRB process was established as an integral requirement of the
Common Rule for the purpose of reviewing the informed consent process,
reviewing the balance of the risks to the subject with the benefits to either
the subject or society at large, and to ensure the equitable selection of
subjects. An IRB must carry out these duties based on a thorough
assessment of all aspects of the research design and systematic consid-
eration of alternatives.
THE NAT'L INST. OF JUSTICE, DEP'T OF JUSTICE, INTRODUCTION TO HUMAN SUBJECT AND
PRIVACY PROTECTIONS AT THE NATIONAL INSTITUTE OF JUSTICE, para. 5, at http://www.ojp.
usdoj.gov/nij/humansubjects/hs 01.html (last updated Sept. 13, 2003),
" Ezekiel J. Emanuel et al., Tfe Crisis in Human Participants Research: Identifying the
Problems and Proposing Solutions, Paper Presented Before the President's Council on
Bioethics (Sept. 12, 2002), available at http://www.bioethics.gov/background/emanuel
paper.html.
See, e.g., Katherine Q. Seelye, EPA Weighs Pesticide Tests on Humans, N.Y. TIMES, Nov.
28, 2001, at A 18 (citing comments of Ray McAllister, Vice-President of the American Crop
Protection Association).
75 See, e.g., Vera Hassner Sharav, Children in Clinical Research: A Conflict ofMoral Values,
3 AM. J. BIOETHICS 1, 1 (2003).
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Although there may be a benefit to human beings generally from the
knowledge gained through this research, when pesticides are tested on human
subjects, the individual human research subject rarely benefits directly from
the experiments.76
Some critics complain that human studies, because they are carried out
on human adults, leave unanswered the questions of safety thresholds for
children. 77 This is troubling because "[t]here is broad scientific consensus that
children are especially vulnerable to the adverse effects of pesticides. Chil-
dren's low body weight and rapidly growing organ systems combine to make
them more susceptible to many toxic substances, including pesticides. '' 78 In
76 But see SAB & FIFRA SAP, supra note 25, at 25-26 (arguing that some individuals
actually benefit directly from improved health care and monitoring due to the testing
procedures and availability of healthcare facilities).PANNA, supra note 57, at para. 4. The Food and Drug Administration ("FDA") also faced
ethical issues with respect to whether it should allow, or even require, drug testing on human
children. In the early 1990s, many drug companies did not do clinical tests on children, in
part because of high costs and unwillingness of parents to volunteer their children for
research. FOOD & DRUG ADMIN., FROM TEST TUBE TO PATIENT: IMPROVING HEALTH
THROUGH HUMAN DRUGS 79 (1999) [hereinafter FDA 1999]. During this time the FDA
approved very few drugs for pediatric use because a regulation issued in 1979 required
clinical studies in children prior to marketing the drug specifically for pediatric use. U.S.
FOOD & DRUG ADMIN., FROM TEST TUBE TO PATIENT: IMPROVING HEALTH THROUGH
HUMANDRUGS 66 (1996) [hereinafter FDA 1996]. Many of the drugs used on children at the
time were not FDA-approved, but over time doctors determined pediatric dosages through
their own clinical experiences. See, e.g., FDA 1999, supra, at 79 (off label use). In 1994, the
FDA amended the 1979 regulation that allowed drugs to be labeled for use in children if the
disease that was being treated had a significantly similar affect in adults and children.
Specific Requirements on Content and Format of Labeling for Human Prescription Drugs;
Revision of "Pediatric Use" Subsection in the Labeling, 59 Fed. Reg. 64,240, 64,240 (Dec.
13, 1994) (to be codified at 21 C.F.R. pt. 201). The new adaptation of the original regulation
allows the FDA to request firther testing on the pediatric population to determine proper
labeling for widely used drugs. Id. at 64,242. Following the amendment, FDA encouraged
testing on children to obtain the proper pediatric dosages. FDA 1996, supra, at 65. FDA
supported these tests because the speed and functioning of children's metabolisms effect the
amount of drug they need; therefore, testing on adults is inadequate to determine the dosage.
Id. at 64. FDA's support of these tests on human subjects, differs from EPA's allowing
pesticide testing on human children, because, with respect to pesticides, individual research
subjects will not benefit directly from the experimentation. In pediatric drug tests, unlike
pesticide toxicity studies, experimental drugs may, in fact, benefit the individual child
subject. See, e.g., FDA 1999, supra, at 78. If EPA allowed pesticide testing on
children-which it has never indicated it will-the public as a whole may be advanced, but
the individual subjects of the test likely will not. This same position would be true for human
adult research as well.
78 Press Release, Environment & Human Health, Inc., Lawn-care Pesticides Pose Significant
Threats to Human Health and the Environment, Warns New EHHI Report (June 24, 2003),
available at http://www.chhi.org/pesticides/prriskreport.html. See generally, JOHN WARGO
ET AL., ENV'T & HUMAN HEALTH, INC., RISKS FROM LAWN-CARE PESTICIDES: INCLUDING
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addition, because children's height causes them to be closer to the ground
than adults, children face more exposure to pesticides and other harmful
agents than the adults upon whom the tests are conducted.79
Children are often more exposed to pesticides than are adults
in residential settings. Children play or crawl on grass or
floors where pesticide powders and granules normally settle.
Some lawn-care chemicals are neurotoxic, others are
carcinogenic, and still others are suspected to act like human
hormones once they enter our bodies."0
There is substantial cause for concern about the long-term risk to children
from exposure to these pesticides."
In addition to the fact that the human studies at issue do not provide
information specifically regarding safe exposure levels for children, they raise
concerns because of the scientific methods employed. For example, many
human studies tend to involve very small sample sizes, 2 probably because
small studies are less costly and put fewer human subjects at risk. Although
studies using small sample sizes can certainly provide information regarding
how those few people reacted to the pesticides, the results from these studies
are extrapolated to larger populations much less reliably than studies using
large sample sizes.
Finally, some studies are carried out on human subjects who have an
interest in the product being tested. 3 For example, Ciba-Geigy used its own
managers as research subjects.8 4 These subjects were not disinterested. To
further their own careers, they had an interest in producing research that
would portray the tested pesticide in a positive light.
INADEQUATE PACKAGING AND LABELING 23 (Jane Bradley & Susan Addis eds., 2003)
(describing the unique health risks of pesticides to children), available at http://ehhi.org/
pubs/pesticides/ehhi_pesticides full.pdf.
SAB & FIFRA SAP, supra note 25, at 14-15.
So Press Release, Environment & Human Health Inc., supra note 78.
81 Id.
82 See, e.g., Steve Stecklow, Side Effect: New Food Quality Act Has Pesticide Makers Doing
Human Testing-Firns Say Tougher Standards Force Them to Prove Safety of Toxic
Chemicals-Bug Killers andAlzheimers, WALL ST. J., Sept. 28, 1998, at Al.
93 id.
4 Id.
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III. EVOLVING POLICY
A. Policy Under the Clinton EPA
Long before EPA under former President Bill Clinton faced the problem
of human studies, EPA staffers under former President Richard Nixon
suggested that the Agency should encourage such studies on certain
pesticides.8 5 "Nixon-Ford EPA Administrator Russell Train ... said he was
'shocked and appalled' by the proposal, and that 'the thing should have been
shut off at the very start without even dignifying it by a referral to an advisory
board.'" 8 6 In several instances, EPA officials have rejected data from human
tests done by the Nazis in the 1940s. 7
During the Clinton administration, EPA had no formal policy con-
cerning private pesticide toxicity studies that use human subjects.88 However,
following the release of the Environmental Working Group's report, The
English Patients, which revealed serious ethical issues in the use of human
subjects in private pesticide toxicity studies, the Clinton EPA issued a
moratorium on its consideration of data from those studies.89 The Agency
specifically indicated that it would not rely on testing human subjects to set
NOAELs in the regulation of pesticides until it could establish a formal
policy.90 The Agency said it was "concerned about the possibility of increased
human testing as a way to potentially avoid some of the protections that the
" Press Release, Natural Res. Def. Council, supra note 70. For a discussion on earlier policy
and guidelines, see Heidi Gorovitz Robertson & Samuel Gorovitz, Pesticide Toxicity, Human
Subjects, and the Environmental Protection Agency's Dilemma, 16 J. CONTEMP. HEALTH L.
& POL'Y 427, 446-47 (2000) (discussing early Office of Pesticide Programs requirements,
their Pesticide Assessment Guidelines, and the FIFRA provision that prohibits pesticide
research on humans except in certain circumstances, FIFRA § 12(a)(2)(P), 7 U.S.C. §
136j(a)(2)(P) (2000)).
s6 Id. (citing Bob Wyrick, EPA Officials Devised Cancer Tests on People; EPA Officials
Devised Test to Feed Cancer-Causing Fungicides to People, WASH. POST, June 23, 1977,
at Al).87 Id.
" Karen L. Werner, Trade Associations Seek Reconsideration of Late 2001 Interim Human
Testing Policy, [21] Daily Env't Rep. (BNA) A-4, A-5 (Jan. 31, 2002) [hereinafter Werner,
Trade Associations].
" Id. (indicating the moratorium was issued in response to The English Patients). See
generally, ENVTL. WORKING GROUP, THE ENGLISH PATIENTS: HUMAN EXPERIMENTS AND
PESTICIDE POLICY (1998), available at http://www.ewg.org/reports/english/English.pdf
detailing pesticide studies conducted on English citizens and submitted to EPA).
Werner, Trade Associations, supra note 88, at A-4; see also Press Release, Natural Res.
Def. Council, supra note 70.
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Food Quality Proection Act establishe[d]." 9 Before this announcement, EPA
had long evaluated these studies and the data they produced, on a case-by-
case basis.92 In December 1998, the Agency stated that "[n]o human test data
has been used by EPA for any final decisions about acceptable levels of
pesticide under the new food safety law."93
1. The Joint Science Advisory Board and FIFRA Scientific Advisory
Subcommittee
In November 1998, EPA appointed a joint subcommittee of SAB and
FIFRA SAP and directed that group to provide guidance on ethical consider-
ations related to evaluating human studies submitted to the Agency in support
of requests for pesticide registrations.94 The joint SAB and SAP subcommit-
tee included bio-ethicists, medical doctors, environmental and occupational
health doctors, public health doctors, federal officials, and federal experts.95
9' Press Release, Natural Res. Def. Council, supra note 70 (quoting John H. Cushman, Jr.,
Group Wants Pesticide Companies to End Testing on Humans, N.Y. TIMES, July 28, 1998,
at A9).
92 Werner, Trade Associations, supra note 88, at A-5. Pesticide industry representatives
criticized the Agency for this decision alleging that it was inconsistent within the Agency. Id.
They argued that the Agency, itself, conducted controlled human experiments at its facilities
in Research Triangle Park, N.C., on, for example, toxic responses to methyl tertiary butyl
ether, but sought to prohibit such research on pesticides. Id. EPA replied that the interim
policy applied throughout the Agency. Id.3 ENVTL. PROT. AGENCY, SCIENTIFIC ADVISORY PANEL (SAP)/SCIENCE ADVISORY BOARD
(SAB) DECEMBER 1998 MEETING: EPA STATEMENT ON HUMAN TESTING (1998), available
at http://www.epa.gov/scipoly/sap/l998/december/epastmt.htm.
' Science Advisory Board/Scientific Advisory Panel; Notification of Public Advisory
Committee Meeting: Open Meeting, 63 Fed. Reg. 64,714, 64,714 (Nov. 23, 1998). EPA
provided a list of Charge Questions for the joint SAB and SAP subcommittee. These
questions ranged from the potential value human studies serve, what factors EPA should
consider, how to weigh risks and benefits of the studies, how guidance could be applied in
the future, and how to best ensure compliance with any future EPA standards. Scientific
Advisory Panel, Envtl. Prot. Agency, Scientific Advisory Panel (SAB)/Science Advisory
Board (SAB) December 1998 Meeting: Charge Questions for SAB/SAP Joint Subcommittee
on Data from Human Subjects, at http://www.epa.gov/oscpmont/sap/1998/december/
sabquest.htm (last updated Dec. 18, 2003); see Robertson & Gorovitz, supra note 85, at 448-
50.
9' For a list of the committee members, see ENVTL. PROT. AGENCY, MEMBERS OF THE
DECEMBER 10-11, 1998 JOINT SCIENTIFIC ADVISORY PANEL (SAP)/SCIENCE ADVISORY
BOARD(SAB) HUMAN TESTING ETHICS MEETING (1998), at http://www.epa.gov/scipoly/
sap/1 998/december/sabmbrs.htm (last visited Oct. 20, 2003) [hereinafter 1998 SAB & SAP
MEETING MEMBERS]; ENVTL. PROT. AGENCY, A JOINT SCIENCE ADVISORY BOARD (SAB)
AND FIFRA SCIENTIFIC ADVISORY PANEL (SAP) OPEN MEETING, (1999), at
http://www.epa.gov/scipoly/sap/1999/november/members.htm (last visited Oct. 20, 2003)
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Thejoint SAB and SAP met for the first time December 10-11, 1998 for
a Human Testing Ethics meeting.96 Before the second meeting on November
30, 1999, subcommittees met via conference calls to identify issues needing
resolution and to expedite the process.97 Because the committee needed fur-
ther information regarding EPA's charge, it disseminated an EPA-created
background paper prior to the second meeting. This paper was to give the
committee members a more complete understanding of the issues and provide
examples of the types of human studies that third parties have submitted to
EPA.9"
During the two meetings of the combined subcommittees, which took
place approximately a year apart, the panel heard testimony from experts
from the many universities and scientific communities that made up the
panel, in addition to experts brought in to address specific topics. 99 During
this process, the committee reached the conclusions presented in its report
released on September 11,2000.100 The committee reached unanimous agree-
ment on a series of basic ethical and scientific findings, outlining these before
answering EPA's Charge Questions.' 0 ' Following agreement on these basic
thereinafter 1999 SAB & SAP MEETING MEMBERS].
6 Science Advisory Board/Scientific Advisory Panel; Notification of Public Advisory
Committee Meeting; Open Meeting, 63 Fed. Reg. 64,714, 64,714-15 (Nov. 23, 1998).
9' See, e.g., Nancy Fiedler, Remarks at the Open Meeting of the Joint Science Advisory
Board (SAB) and Scientific Advisory Panel (SAP) on Data from Testing on Human Subjects
24-25 (Nov. 30, 1999), transcript available at http://www.epa.gov/scipoly/sap/1999/
november/jointsab.sap.pdf (discussing the issues that arose in the conference calls).
" See id. at 24. See generally STAFF BACKGROUND PAPER, supra note 9 (discussing the
issues before the committee).
" See 1999 SAB & SAP MEETING MEMBERS, supra note 95; 1998 SAB & SAP MEETING
MEMBERS, supra note 95.
'oSAB & FIFRA SAP, supra note 25.
1o1 Id. at 1-2. These basic points were:
a) Any policy adopted by the Agency should reflect the highest
standards ofrespect for human subjects and should prohibit research
protocols that override the interest of subjects in order to obtain
useful data.
b) If it can be justified at all to expose human subjects intentionally to
toxic substances, the threshold ofjustification for such action should
be very high.... The risks of allowing such experimental exposures
of humans include the possible involvement of less than fully
informed participants, unanticipated health consequences, the
exposure of large numbers of subjects, and skewed use in
developing countries.
c) Bad science is always unethical; research protocols that are
fundamentally flawed ... are unjustifiable.
d) If the use of human subjects in pesticide testing can be justified, that
justification cannot be to facilitate the interests of industry or of
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principles, the entire committee, minus two members, agreed that under
"particular circumstances.. . dosing of humans could be scientifically and
ethically acceptable."' 10 2 In its report, the joint SAB and SAP subcommittee
indicated that pesticides might be tested on humans, but suggested that EPA
require such research be pre-approved by an IRB in accordance with the
Common Rule. 103 The panel suggested that EPA have an oversight committee
or internal ethics review organization specific to human subjects research. "0
The panel also stated that "developing" humans from fetus to adolescents
should not be exposed to pesticides in research under any circumstances. 0 5
Next, the panel allowed that unethical research should not be automatically
rejected. 6 And, significantly for the pesticide industry, the joint SAB and
SAP subcommittee report found that human subject testing should not be
used to lower the NOAEL. °7 A minority of the panel, however, wrote that
human tests of pesticides are unscientific, unsafe, and inherently unethical.
agriculture, but only to better safeguard the public health.
e) Any policy adopted by the Agency must reflect a special concern for
the interests of vulnerable populations ....
f) Unintended exposures provide valuable opportunities for research;
it is an error not to take full advantage of such opportunities to gain
major information through careful incident follow-up.
g) In considering research protocols, it is not enough to determine a
risk/benefit ratio; it is important also to consider the distribution of
risks and benefits, and to ensure that risks are not imposed on one
population for the sake of benefits to be enjoyed by another.
Id.
102 Id. at 2.
,03 Id. at 3.
,04 Id. at 3, 36-37.
Ios d. at 15.
'06 SAB & FIFRA SAP, supra note 25, at 30.
107 Id. at 12.
'08 The minority report expressed the dissatisfaction of Drs. Needleman and Reigart with the
committee's process, and their belief that the final report increases the health risks of
exposure for children, a conclusion they could not support as doctors of pediatrics. SAB &
FIFRA SAP, supra note 25, at app. C- 1, C-3. The transcript from the first meeting was not
made available until June of 1999, nearly five months after the meeting. Id. Out of the
original thirteen members, four members signed the minority report and four members signed
a letter of support for the minority statement. Id. According to some members, the initial
reports generated from the first meeting did not accurately represent the statements and
conclusions of the members. Id. The initial report did not contain the reservations members
of the committee held for the testing of organophosphate compounds on humans, and the
report presented a majority view that pesticides could not be differentiated from other
chemical compounds when that was the perspective of one member of the committee. Id. at
C- 1, C-2. The minority report was not willing to support the minimum standard of statistical
data provided in human testing of pesticides and did not find adult testing at all applicable
to children. Id. at C-2. Finally, the majority was concerned that justifying situations in which
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The joint SAB and SAP subcommittee report initially appeared to give
the pesticide industry approval to conduct human-based research in controlled
circumstances. The most devastating aspect of this report for the pesticide
industry, however, was the panel's statement that it "would not support
human experimentation primarily to determine a [NOAEL]" because "[g]en-
erating such data pose[s] ethical concerns," and that "generally, human
dosing experiments are not appropriate if the primary intent of the study is to
determine or revise a NOEL or NOAEL so as to eliminate the interspecies
uncertainty factor.""' 9 The report indicated that the ethical reasoning for the
testing needs to be weighed alongside the scientific authenticity of the tests
before EPA can determine the value of the data produced. The report's insis-
tence that human testing data not be used to reduce NOAELs or eliminate the
tenfold factor would, if adopted, effectively render such research ineffectual
for the pesticide industry's purposes." 0
Also, according to the report, small studies of adverse pesticide effects
on human subjects are not indicative of the effect of that pesticide on the
general population."' The report describes the following example. There are
18.9 million children under the age of five in the United States." 2 Ifjust one
percent of those children are affected by a pesticide, 189,000 children would
be affected." 3 In a human-based study of one-hundred participants, only one
person would suffer an effect. The sample sizes for the human-based pes-
ticide toxicity studies submitted to EPA have been considerably smaller.'
In fact, they have varied from five to sixty people," 5 samples so small that it
is highly likely that an adverse effect might not be revealed. Yet, in the gen-
eral population, 189,000 children could show adverse effect not revealed by
the small sample.
According to the Agency, EPA wants "to rely on data meeting the
highest scientific and ethical standards-the most appropriate and the most
reliable available, able to support the most accurate assessments of potential
studies would be acceptable opened the door to more studies. SAB & FIFRA SAP, supra
note 25, at app. C-2.
"o Id. at 11, 17 (emphasis omitted).
11o See id. at 3 ("If the use of human subjects in pesticide testing can be justified, that
iustification cannot be to facilitate the interests of industry or of agriculture ...
"Id. at app. B-1.
112 Id.
113 Id.
114 See, e.g., Stecklow, supra note 82.
15 Id.
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risk."" 6 To meet this goal the joint SAB and SAP report suggested that the
number of subjects needed to make a reliable no-effect assertion with eighty
percent confidence would be between six thousand and fourteen thousand
participants, vastly more participants than in any studies submitted to EPA
to date."17
The panel concluded that the intention behind the testing of pesticides
on humans is relevant, and that EPA should not allow the results of such tests
to influence its decisions to revise or determine a NOAEL, or to circumvent
the interspecies uncertainty factor." 8 This suggestion alone would be suf-
ficient to induce the pesticide manufacturers to lobby EPA not to adopt the
SAB and SAP suggestions as policy. If, as the SAB and SAP panel suggests,
their studies could not be used to determine a lower NOAEL, or to eliminate
the tenfold interspecies uncertainty factor, it would not be worth the indus-
try's considerable investment to conduct human-based research.
Regarding the FQPA tenfold factor for the protection of human children,
the SAB and SAP subcommittee stated that
[t]here seems little probability that high quality data relevant
to children can be derived from studies on adults at this time,
or in the foreseeable future. The Subcommittee rules out the
only alternative, the testing of children and adolescents, as
being ethically unacceptable. There are too many unknown
dangers to justify the effort, even under the most extra-
ordinary circumstances." 9
This is a particularly awkward finding for the joint SAB and SAP subcom-
mittee. The current method for determining NOAELs is to use the tenfold or
one-hundred-fold factor for extrapolating data from animal tests to adults and
children, respectively. 2 ' Even if data from adult human tests were deemed
acceptable for determining a NOAEL for adults, the panel was not willing to
condone eliminating the additional tenfold factor for determining a NOAEL
for children and adolescents based on the relative adult data.'2' Although the
116 STAFF BACKGROUND PAPER, supra note 9, at 3.
7 SAB & FIFRA SAP, supra note 25, at app. B-1.
.
8 Id. at 17.
"
9 Id. at 15.
120 See OPP DRAFT POLICY, supra note 30, at 25-26.
121 See SAB & FIFRA SAP, supra note 25, at 15.
[Vol. 28:205
How MANY TIMES Do I HAVE TO TELL YOU?!
joint SAB and SAP subcommittee found some value in the collection of hu-
man testing data12 2 as discussed above, it did not approve of using the data to
establish lower NOAELs.' 23 Without using the data to lower NOAELs, the
human testing data is of little value to the pesticide industry as it will not
increase the ability to obtain new approvals of pesticides or re-approvals of
existing pesticides.
According to members of the joint SAB and SAP subcommittee, there
are scientific and ethical flaws in the way human tests are designed. 24 One
flaw, as discussed above with respect to children, is that these tests tend to
"have very small numbers of subjects and look at very crude outcomes and
come to the conclusion that no health effects were seen.' ' 25 According to the
committee, for the tests to be a reliable indicator, they would have to use
many more human subjects, which would mean requiring larger numbers of
people to swallow or inhale more pesticides over an extended period of
time. 126 In fact, to conduct the highest quality study from the scientific per-
spective, you would have to establish the entire risk spectrum by killing
people. 127 This is why the problem of establishing a policy for these studies
does not solely lie in the realm of good science; it also concerns good
ethics. 128
Although the joint SAB and SAP subcommittee submitted its report to
EPA, some in the Agency saw a lack of clarity in its advice, perhaps due to
the existence of a minority opinion, perhaps merely because the issue is com-
plex.'29 Some in EPA called for greater clarity on the issue, following the
122
[H]uman experimental data would serve as a valuable transition to further
research on both exposure assessment and toxic mechanisms. In such a
role, human experiments would pose fewer of the ethical quandaries that
arise when they are used simply to establish a NOAEL that lacks cogent
scientific value and whose purpose can be interpreted as simply an
argument for higher permissible exposure levels.
Id. at 12 (emphasis omitted).
" Id. at 11 ("One additional caveat concerning such intentional exposure is important-the
Subcommittee, in general, would not support human experimentation primarily to determine
a No Observed Adverse Effects Level (NOAEL).") (emphasis omitted).I24 Id. at app. C-2; see also PANNA, supra note 57.
125 PANNA, supra note 57 (quoting Dr. Herbert Needleman, pediatrician at the University
of Pittsburg).126 Id.
127 Id.
28 Id.
129
We [EPA] convened a blue ribbon advisory committee jointly with
two groups in EPA that advise us, the Scientific Advisory Panel and the
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final report. For example, the Science Director for the Office of Children's
Health Protection ("OCHP"), criticized the report in several places for lack
of clarity.130 In particular, he sought expansion of the finding that the panel
would not support human testing when the primary purpose of such testing
is to determine a NOAEL.1
3 1
Critics outside the Agency also found the report unclear. For example,
the report says, "[iln no case should developing humans... be exposed to
neurotoxic chemicals.' ' 2 James D. Wilson, Senior Fellow of Resources for
the Future's Center for Risk Management, finds this statement unworkable
Science Advisory Board and they took several years to meet about and
discuss the questions involving this type of testing.
They had representatives from the human research community, the
bioethicists, toxicologists, a very broad group of disciplines and a very
respected group of people who are on the committee.
They met several times in public meetings, took comments, and
developed and issued a report in September of 2000.
The report has both areas of consensus and areas of disagreement.
In particular the committee divided on the acceptability of no adverse-no
observed adverse effect level studies or what we call NOAEL studies. One
group, a minority group, said that these studies in humans with human
subjects should not be accepted under any circumstances. The other group
identified a set of criteria that they suggested EPA consider.
After mulling it over and changing administrations and mulling it
over some more and then mulling it over some more, we decided that this
really was an area that continued to be controversial, that continued to be
one where at least with respect to this critical issue of NOAEL studies we
felt we wanted more guidance.
Jordan, supra note 2, at 174-75 (emphasis added).
'30 Memorandum from Michael Firestone, Science Director, Office of Children's Health
Protection to Donald Barnes, Executive Director, Science Advisory Board, Report of the
Joint SAB/SAP Subcommittee on Data from Testing of Human Subjects (June 8, 2000),
available athttp://www.epa.gov/sab/pdf/fireston.pdf. Firestone stated that the Joint SAB and
SAP subcommittee should resolve four issues:
[C]larify under what circumstances and for what purposes, if any, they
support the intentional dosing or exposure of children to pesticides...[J
clarify findings which state that "intentional administration of pesticides
to human subjects is acceptable, subject to limitations described as ranging
from 'rigorous' to 'severe'". . . [,] expand their findings to include their
recommendation .. .that "the Subcommittee, in general, would not
support human experimentation primarily to determine a NOAEL"...
[and,] consider the clarity of [the overall conclusion] ... that there are no
specific toxicological grounds on which to differentiate pesticides from
other environmental chemicals... since most pesticides are specifically
designed to kill or harm biological organisms often in an indiscriminate
fashion- this is not true for other environmental chemicals.
Id.
131 Id.
132 SAB & FIFRA SAP, supra note 25, at 3.
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because it ties the absolute "in no case" with the undefined term "neurotoxic
chemicals." '133 He raises this, and other statements, as evidence that the report
lacks clarity.'34 Wilson argues that the report, contradicts itself, espousing at
one point the value of holding workshops on statistical design in the context
of identifying NOAELs, yet elsewhere discussing the evils of doing tests
designed to identify human NOAELs.' 35
2. The National Bioethics Advisory Commission
In December 2000, the National Bioethics Advisory Commission
("NBAC"), 136 created to advise the President on the oversight of human
subject research, issued a report recommending the strengthening of federal
regulation of human subject research.33 Like the joint SAB and SAP com-
113 Memorandum from James D. Wilson, Senior Fellow, Resources for the Future's Center
for Risk Management to EPA Science Advisory Board Executive Committee, Comment on
"Use of Data Derived from the Testimony of Human Subjects" 1 (June 8, 2000) (expressing
concern about who has the authority to define neurotoxic chemical), available at
http://www.epa.gov/science l/pdf/wilson.pdf.
134 See id.
135 Id. at 2.
136 President Clinton established NBAC with Executive Order 12975, and declared that the
Commission should provide advice on "the appropriateness.. . of government programs,
policies, assignments, missions, guidelines, and regulations as they relate to bioethical issues"
plus research applications. See 1 NAT'L BIOETHICS ADVISORY COMM'N, ETHICS AND POLICY
ISSUES IN RESEARCH INVOLVING HUMAN PARTICIPANTS, pmbl. (2001), available at
http://www.georgetown.edu/research/nrcbl/nbac/human/overvol 1.pdf [hereinafter 1 NBAC,
ETHICS AND POLICY ISSUES]. NBAC is also responsible for identifying "broad principles to
govern the ethical conduct of research" while accepting suggestions from the National
Science and Technology Council, Congress, and the American public. 1 Id.
137 Karen L. Werner, Bioethics Commission Report Supports Changes to Regulation of
Human Testing, [4] Daily Env't Rep. (BNA) A-2, A-2 (Jan. 5, 2001) [hereinafter Werner,
Bioethics Commission Report]. Although NBAC submitted its final report in December
2000, on May 4, 1999, NBAC Chairman, Harold T. Shapiro sent a memorandum to the
President summarizing general concerns about human subjects protections that had been
raised by the Commission's initial reviews. Letter from Harold T. Shapiro, Chair, National
Bioethics Advisory Commission, to William J. Clinton, President, United States (May 4,
1999), reprinted in NAT'L BIOETHICS ADVISORY COMM'N, ETHICS AND POLICY ISSUES IN
RESEARCH INVOLVING HUMAN PARTICIPANTS, app. B, at 143 (2001), available at
http://www.georgetown.edu/research/nrcbl/nbac/human/overvol 1 .pdf. NBAC was concerned
that:
[1] Federal protections for persons serving as human research subjects
do not yet extend to all Americans[,]
[2] Despite widespread implementation of federal regulations by those
departments and agencies sponsoring substantial amounts of
biomedical research, a number of departments and agencies who
sponsor primarily non-biomedical research or little research overall
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mittee, this commission was composed of experts from multiple fields of
science, medicine, law, ethics, and politics. 138 The relevant committee met
several times before it issued a report, and the current incarnation of the
commission, the President's Council on Bioethics ("PCB"), is still consid-
ering some of the issues that were originally brought before it.139 Although
NBAC met multiple times, it only discussed this particular area of concern
in-depth during one meeting. Although other meetings dealt with the ethics
of using human studies, they did so in a very broad range of circumstances.
1 40
In particular, NBAC recommended the inclusion of "oversight of privately
funded research and creation of an independent federal regulatory office." ''
Although the final report did not specifically address human pesticide testing,
pesticide industry representatives were concerned about the effect the NBAC
report might have on EPA policy setting on this issue. 14' The report generally
recommended "fewer regulations and more guidance," with a focus on "the
have failed to implement these federal protections[,]
[3] Federal protections do not always include specific provisions for
especially vulnerable populations of research subjects[,]
[4] Many federal agencies find the interpretation and implementation of
the Common Rule confusing and/or unnecessarily burdensome[,]
[5] Federal protections are difficult to enforce and improve effectively
throughout the Federal Government, in part because no single
authority or office oversees research protections across all
government agencies and departments[, and]
[6] New techniques are needed to ensure implementation at the local
level.
Id.
'8 For a list of members, see 1 NBAC, ETHICS AND POLICY ISSUES, supra note 136.
139 See NAT'L BIOETHICS ADVISORY COMM'N, NATIONAL BIOETHICS ADVISORY COMMISSION
MEETINGS, at http://www.georgetown.edu/research/nrcbl/nbac/meetings.html (last visited
Oct. 21, 2003). The Charter of the NBAC expired Oct. 3,2001. NAT' L BIOETHICS ADVISORY
COMM'N, NATIONAL BIOETHICS ADVISORY COMMISSION, at http://bioethics.georgetown.
edu/nbac (last visited Oct. 21,2003). The NBAC was reincarnated as the President's Council
on Bioethics. Exec. Order. No. 13,237, 3 C.F.R. 821-823 (2001), amended by Exec. Order.
No. 13,316, 68 Fed. Reg. 55,255 (Sept. 17,2003). The Council is still concerned with human
subject testing although it is not engaged in any formal process on the topic. Leon R. Kass,
Remarks at the First Meeting of the President's Council on Bioethics (Jan. 17, 2002), in THE
PRESIDENT'S COUNCIL ON BIOETHICS: CHAIRMAN'S VISION, available at http://bioethic
sprint.bioethics.gov/about/chairman.html.
1 0 Session one of the September 12, 2002 meeting of the council, discussed Hans Jonas'
essay, Philosophical Reflections on Experimenting with Human Subjects. Leon R. Kass et
al., Remarks at Sixth Meeting of the President's Council on Bioethics (Sept. 12, 2002)
(transcript available at http://www.bioethics.gov/transcripts/sep02/sept12full.html). During
the discussion, the panel addressed both the need for and the ethics behind these tests and
their place in scientific studies. Id.
"41 See Werner, Bioethics Commission Report, supra note 137, at A-2.
142 Id.
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need to make protection of [human] subjects commensurate with the level of
risk" to which they will be subjected. 143 Most relevant to EPA's current
struggle, NBAC also urged the creation of a unified and comprehensive set
of federal regulations governing all human subject research, not just that
funded or carried out by the federal government. '"The NBAC report sugges-
ted that a central, federal office, outside the current organizational structure,
serve as the lead agency for coordination and oversight of human subjects
research.45 Clearly, to enable this, legislation would be required not only to
create a federal oversight office, but also to expand the scope of the Common
Rule's protection to cover the privately-funded and executed human studies,
which are currently outside its scope.'46
According to NBAC, there are numerous problems even with the Com-
mon Rule as it exists and applies today. First, it is difficult to amend because
it is dispersed throughout the regulations of fifteen federal agencies. 47 When
an individual agency amends the Common Rule as applicable to that par-
ticular agency, or creates guidance that changes the agency's interpretation
of the Rule, this creates an inconsistency among the various federal agencies'
applications of the Rule. 48 NBAC suggested that this inconsistency would
undermine the Rule itself.49 Further, NBAC found that the Common Rule is
not very adaptable to new and changing ethical and scientific issues."'
Finally, NBAC was concerned that the Common Rule is more focused on
IRB procedure than on ethical principles.' 5 '
NBAC found that federal agencies find the Common Rule confusing and
difficult to implement.'52 As a result, smaller agencies that sponsor less re-
search do not fully incorporate the Common Rule.'53 NBAC determined that
federal protections do not cover all Americans who are subjects in research,
and there are not always specific provisions concerning vulnerable popu-
lations. 54 Because of these problems, NBAC expressed a preference for a
143 Id.
I" Id.
145 See Werner, Bioethics Commission Report, supra note 137, at A-2.
146 See 1 NBAC, ETHICS AND POLICY ISSUES, supra note 136, at 28.
147 See Werner, Bioethics Commission Report, supra note 137, at A-2.
148 See 1 NBAC, ETHICS AND POLICY ISSUES, supra note 136, at 28.
149 Id. at 11-12.
'50 See id. at 8.
'5' Id. at 13.
352 Letter from Howard T. Shapiro to William J. Clinton, supra note 137.
153 1 NBAC, ETHICS AND POLICY ISSUES, supra note 136, at xi.
154 Id.
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single office to supervise all federal agencies and departments developing
new methods of taking action at a local level.'55 NBAC concluded the more
uniform oversight of human subjects research is necessary to protect human
subjects and allow the continuation of human research that is consistent with
ethical principles.'56
B. Policy under the Bush EPA
1. Pre-moratorium
On November 7, 2001, EPA announced that it would accept data from
pesticide tests that use human subjects.' Interestingly, EPA made this
announcement at a meeting of the American Crop Protection Association, 158
and in doing so, reversed a moratorium on accepting such data established by
the Agency just one year earlier under former President Clinton. 5 9 At this
announcement, the EPA official indicated that although EPA had not yet
adopted an official position, studies of the effects of chemicals on humans
could play a valuable role in risk assessment if the studies are conducted
according to the highest ethical standards. " He noted that this announcement
signaled a change in the Agency's view of human-subject research. 6' Al-
though the administrator noted that there was still no formal policy on
accepting data from third-party human studies, he admitted that EPA had
recently reviewed data from such studies despite the previously issued
moratorium,"' and that EPA was now willing to evaluate data from pesticide
toxicity studies involving human subjects. 63
15' 2 NAT'L BIOETHiCS ADVISORY COMM'N, EmICS AND POLICY ISSUES IN RESEARCH
INVOLVING HUMAN PARTICIPANTS J-4(2001), available at http://www.georgetown.edu/
research/nrcbl/nbac/human/overvo2.pdf.
"
6 See Werner, Bioethics Commission Report, supra note 136, at A-2.
IS PANNA, supra note 57, at para. 1.
158 The American Crop Protection Association, the United States industry trade association
representing manufacturers, distributors, and formulators of pesticides, changed its name to
CropLife America as of January 1, 2002. See Press Release, American Crop Protection
Association, CropLife America Launched (Nov. 30,2001), available at http://www.pestfacts.
org/croplife launch.html.159 PANNA, supra note 57, at para. 1.
160 See Official Sees Rolefor Human Tests, [215] Daily Env't Rep. (BNA) A-9, at A-9 (Nov.
8, 2001).
161 PANNA, supra note 57, at para. 1.
162 Id.
163 Id.
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2. United States Representative Waxman's Reaction
Soon thereafter, Representative Henry Waxman, ranking minority
member of the House Government Reform Committee, voiced serious
concern with EPA's reported plans to rely on industry-sponsored tests of
human subjects to determine the toxicity of pesticides." 6 In addition to
voicing his concern about the substance of the Agency's position, Waxman
indicated concern about the secrecy surrounding the Agency's apparent policy
reversal. 65 According to Waxman, who was involved in the creation of
FQPA, the human studies at issue "have unclear scientific benefit and would
raise ethical problems, since they are used to establish less stringent safety
standards.' 66
In his letter to then-EPA Administrator Christine Todd Whitman,
Waxman requested a list of people with whom her staff had communicated
in reference to human testing. 67 He specifically requested information on
individuals representing the pesticide manufacturing industry and the
documents which either informed this decision on human testing, or
documented it.' 68 He requested "a list of pesticide risk assessments using
human data, and a list of pending reviews where the human data will be
reviewed.' 169 Waxman asked that EPA provide this information by December
21,2001.70 In his letter, Waxman accused EPA of ignoring the guidelines set
by the 1998 joint SAB and SAP subcommittee, which recommended that
human studies not be used to establish NOAEL. 7' According to Waxman's
office, EPA has not been forthcoming with the information, replying to his
requests with a short, unresponsive letter.
72
" Karen L. Werner, Waxman Expresses Strong Reservations About Human Pesticide Tests,
EPA Policy, [236] Daily Env't Rep. (BNA) A-2, at A-2 (Dec. 11,2001) [hereinafter Werner,
Waxman Expresses Reservations].
165 Id.
166Id.
167 Id.168 Id.
169 See Werner, Waxman Expresses Reservations, supra note 164, at A-2.
170 Id.
171 Id.
1'Telephone Interview with Greg Dotson, Counsel, Office ofRepresentative Henry Waxman
(Mar. 24, 2003).
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3. Moratorium
Shortly after the announcement at the pesticide industry event, however,
EPA made another announcement. On December 14, 2001, EPA reversed its
November 7 announcement. EPA indicated, by press release,'73 that it would
not consider or rely on any human studies in its regulatory decision-making,
whether submitted previously or in the future, if those studies were conducted
by third parties that used intentional dosing of human subjects for the purpose
of quantifying a toxic endpoint. 74 This press release amounted to a new
moratorium on accepting data from third party human subjects studies of
pesticide toxicity. At the same time, the Agency also announced that it was
asking the National Academy of Sciences ("NAS") to answer some questions
of science, policy, and ethics as part of EPA's attempt to draft a permanent
policy on the subject. 175
Further, EPA indicated that if it was "legally required to consider or
rely" on any human subject research during the interim period, it would "as-
semble a Science Advisory Board subpanel to review and comment on scien-
tific appropriateness and ethical acceptability of the study in question ... ."76
The Agency indicated that it would provide an opportunity for public
involvement. 177 EPA further pledged that it would "allow the Science
Advisory Board to review all available information on the study" and "[t]his
external review would occur prior to [the agency's] consideration of the
study" at issue.178
During this moratorium period, while EPA was to be awaiting a re-
placement policy recommendation, pesticide manufacturers lobbied EPA to
reconsider the interim moratorium; they asked EPA instead to consider the
173 Press Release, Envtl. Prot. Agency, Agency Requests National Academy of Science Input
on Consideration of Certain Human Toxicity Studies; Announces Interim Policy (Dec. 14,
2001), available at http://www.epa.gov/epahome/headline2_121401 .htm [hereinafter EPA
Requests NAS Input]; see also, Phibbs, supra note 31, at A-3.
S14 EPA Requests NAS Input, supra note 173; Jordan, supra note 2, at 177.
"' See Werner, Trade Associations, supra note 88, at A-4; see also note 225 infra for the
cuestions EPA posed to NAS.
1 6 EPA Requests NAS Input, supra note 173.177 Id. EPA is currently operating an open docket into which interested parties may submit
comments. See ENVT'L. PROT. AGENCY, DOCKET ID OPP 2003-0054, PESTICIDES:
PROCEDURES CONCERNING THE DEVELOPMENT, MODIFICATION, AND IMPLEMENTATION OF
POLICY GUIDANCE DOCUMENTs;NOTICEOFAVAILABIUTY (Mar. 12,2003), athttp://cascade.
epa.gov/RightSite/dk_public collectiondetail.htm?ObjectType=dkdocket collection&c
id=OPP-2003-0054&ShowList=items&Action=view.
17' EPA Requests NAS Input, supra note 173.
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results of tests performed on human subjects as it makes regulatory decisions
on pesticides. 7 9 For example, CropLife America and the American Chemistry
Council ("ACC") asked EPA to evaluate the results of studies submitted to
the Agency prior to December 14, 2001, on a case-by-case basis, pending the
conclusion of the NAS review. 80 CropLife America strongly urged EPA not
to ignore the results of studies that had been "performed consistent with
accepted national and international standards, as well as the... Common
Rule guidelines."'' CropLife America further argued that there was no lawful
or reasoned basis for the Agency to ignore the results of these scientifically
valid studies. 8 2 Finally, CropLife America charged that EPA should not have
implemented the interim moratorium in the absence of a notice and comment
period because its implementation would "definitively constrain the agency's
decisionmaking processes under FFDCA [Federal Food, Drug, and Cosmetic
Act "'83] and FIFRA [Federal Insecticide, Fungicide, and Rodenticide Act' 4]"
and would thus constitute a "legislative rule."' 85 CropLife America asked the
Agency to respond to the industry request by February 1,2002, and threaten-
ed legal action in the absence of a timely and favorable reply.
86
4. The CropLife America Lawsuit
By letter in January 2002, two major pesticide industry trade associa-
tions, CropLife America and the ACC, asked EPA to reverse the policy it had
issued in a press release, which indicated that it would not rely on the results
of tests involving human subjects until it received the requested report on the
subject from the NAS. "7 The associations indicated that barring satisfaction,
they would sue the Agency in an attempt to have the new interim policy re-
versed. 188
179 Letter from Jay Vroom, President, CropLife America and Has Shah, Manager, Biocides
Panel, American Chemistry Council, to Stephen Johnson, Assistant Administrator, Office of
Prevention, Pesticides and Toxic Substances, EnvtI. Prot. Agency (Jan. 24, 2002), available
at http://www.pestlaw.com/x/comments/2002/CLA-20020124A.html [hereinafter Letter from
Jay Vroom & Has Shah to Stephen Johnson].
180 Id.
181 Id.
182 Id.
1:3 21 U.S.C. §§ 301-399 (2000).
1 4 7 U.S.C. §§ 136-1 3 6 y (2000).
1' See Letter from Jay Vroom & Has Shah to Stephen Johnson, supra note 179.
1
86 Id.
... Werner, Trade Associations, supra note 87, at A-4 (citing Letter from Jay Vroom & Has
Shah to Stephen Johnson, supra note 179).
188 See Werner, Trade Associations, supra note 88, at A-4.
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EPA did not reverse the interim policy, and Croplife America sought
relief from EPA's directive in the D.C. Circuit Court of Appeals.'89 The
lawsuit was an attempt to force the Agency to return to an earlier policy and
consider the results of privately funded and conducted studies involving
human subjects in its regulatory decision-making.9 The court granted review
of the directive and heard oral arguments on March 17, 2003.19
In its petition for review, CropLife America argued that the moratorium
on considering data from third party human studies, issued by EPA in a press
release on December 14, 2001, is a de facto regulation. 192 In issuing this new
"regulation," CropLife argued that EPA changed the old internal policy of
evaluating pesticide tests conducted on human subjects on a case-by-case
basis, to a policy in which the Agency would not evaluate these studies in the
absence of a new, formal policy.' 93 The charge was that this change amounted
to the creation of a regulation with no proper notice and opportunity for
public comment as required by the Administrative Procedure Act ("APA"). 194
CropLife America argued that this de facto regulation was illegal
because EPA promulgated it in violation of the APA requirement that
agencies provide notice and opportunity for comment in the course of rule-
making.' 95 In addition, CropLife America argued that the moratorium violated
an FFDCA requirement that EPA consider all relevant, reliable data in
making pesticide decisions' 96 and a provision of FIFRA that requires human
participants in pesticide research to be fully informed of the risks of and
voluntarily consent to their participation. 197 CropLife America argued that
this FIFRA provision implies that human studies are valid if the studies meet
these requirements.'98 Finally, CropLife America argued that the "regulation"
is arbitrary, capricious, and otherwise not in accordance with the law.' 99
' Petitioner's Petition for Review at 1, CropLife Am. v. EPA, 329 F.3d 876 (D.C. Cir.
2003) (02-1057), available at http://www.pestlaw.com/x/courts/ACPA20020212.html.
9 Lowy, supra note 61, at A14.
'9, CropLife Am. v. EPA, 329 F.3d 876 (D.C. Cir. 2003).
' See id. at 878.
193 Id.
194 Id.; see also 21 U.S.C. § 346a(e) (2000) (outlining EPA's current requirements for issuing
regulations through notice and comment procedures).
19-CropLife Am., 329 F.3d at 878.
' Petitioner's Petition for Review at 1, CropLife Am. (02-1057), supra note 189; see 21
U.S.C. § 346a(b)(2)(D) (2000).
19 Petitioner's Petition for Review at 1, CropLife Am. (02-1057), supra note 189; see 7
U.S.C. § 136j(a)(2)(P) (2000).
'9 Petitioner's Petition for Review at 1, CropLife Am. (02-1057), supra note 189.
Id. (citing 5 U.S.C. § 706(2)(A) (2000)).
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In support of these positions, CropLife America suggested that should
the court fail to require EPA to consider human studies, EPA would make
erroneous risk assessment decisions and cause irreparable harm to the pesti-
cide manufacturers. 200 For these reasons, CropLife America asked the "[c]ourt
to set aside the [press release-issued] moratorium" and require EPA to
consider, on a case-by-case basis, "available human clinical data and giv[e]
the data the weight that it deserves according to its scientific relevance,
reliability, and probative value, as well as any relevant ethical standards. 20 '
During the oral arguments, counsel for EPA challenged Croplife
America's standing to bring this suit, argued that the directive was not a
regulation subject to the APA notice and comment requirements, and noted
that during the time that the directive was in place the Agency had, in fact,
allowed submission of some studies done on human subjects.202 Croplife
America's other opponents argued that pesticide producers support studies
involving human subjects primarily to avoid EPA's risk assessment formula
that requires the Agency to impose a threshold of exposure for humans that
is ten times more stringent than that indicated for animals in animal-based
research.03 For children and other sensitive populations, the threshold is ten
times more stringent than that which would apply to the general public.2°'
The court found for CropLife America, holding that the directive
amounted to a binding regulation, unlawfully issued for failure to give notice
and an opportunity for public comment as required by the APA. 205 The court
reinstated EPA's most recent policy of applying a case-by-case analysis of
research done on human subjects, until the Agency properly replaces the
policy.2
6
Although this ruling appears to require EPA to return to a policy in
which it considers data from third party pesticide toxicity studies on human
subjects, in practice, there is no real change that arises from this decision.
Even after EPA issued the directive, it never fully enforced the moratorium.
20 7
The Agency continued to review pesticide tests that were done privately,
making the statement more symbolic than a true regulation.2 °s
200 Petitioner's Petition for Review at 1, CropLife Am. (02-1057), supra note 189.
201 Id.
202 See CropLife Am. v. EPA, 329 F.3d 876, 880 (D.C. Cir. 2003).
203 Lowy, supra note 61, at A14.
204 Id.
205 CropLife Am., 329 F.3d at 879.
206 Id.
207 See PANNA, supra note 57, at para. 1.
208 Id.
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Even so, EPA still states that it neither encourages nor requires research
on the effects of pesticides on humans, and the Agency has not yet adopted
any formal policy or set standards for such studies.2 9 Now, through its
current request to NAS, EPA is again seeking, as it has several times pre-
viously, to assess the scientific and ethical acceptability of these studies when
they are submitted to the Agency for consideration in support of an appli-
cation for pesticide registration.210
5. The Bishop Amendment: An Attempt to Reinstate the Moratorium
Through Legislation
On July 25, 2003, following the CropLife America decision, Rep-
resentative Timothy Bishop introduced an amendment to House Bill 2861,
that would legislatively reinstate the ban on using humans for the testing of
pesticides.1 This amendment was agreed to by a voice vote in the House.21 2
The bill passed the House of Representatives by a vote of 316 to 109 on July
25,213 and was sent to the Senate on July 28, 2003.214 The bill has progressed
through two readings on the Senate floor, and was placed on the Senate
Legislative Calendar on September 2, 2003.215 If it becomes law, the
moratorium on using pesticide toxicity data from human studies would be
legislatively reinstated.21 6
209 See generally STAFF BACKGROUND PAPER, supra note 9 (lacking a formal EPA policy or
standards on human pesticide studies as of 1999); Press Release, Envtl. Prot. Agency,
Agency Requests National Academy of Sciences Input on Consideration of Certain Human
Toxicity Studies; Announces Interim Policy (Dec. 14, 2001), available at http://yosemite.
epa.gov/opa/admpress.nsf/O/c232a45f5473717085256b2200740ad4?OpenDocument (asking
"the Academy to furnish recommendations regarding the particular factors and criteria EPA
should consider to determine the potential acceptability of [human subject] third-party
studies" and stating that "[t]he one thing that all parties agree upon is the need for EPA to
formulate a formal policy on the use of human testing data" (quoting EPA Administrator
Christie Whitman)).
210 Jordan, supra note 2, at 175.
211 Departments of Veterans Affairs and Housing and Urban Development, and Independent
Agencies Appropriations Act, 2004, H.R. 2861, 108th Cong. § 420 (2003).149 CONG. REC. 7,655, 7,695 (2003).
213 2003 HOUSE ROLLNO. 456.
214 149 CONG. REC. 10,045, 10,045 (2003).
215 149 CONG. REC. 10,969, 10,969 (2003).
216 149 CONG. REC. 7,655, 7,694 (2003).
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6. The National Academy of Sciences' Process
On December 14,2001, in addition to announcing the policy change that
led to the Croplife America lawsuit, EPA released a letter to NAS requesting
that NAS "conduct an expeditious review of the complex scientific and
ethical issues posed by EPA's possible use of third-party studies which
intentionally dose human subjects with toxicants to identify or quantify their
effects. ,2 7 EPA asked the NAS to furnish recommendations regarding the
particular factors and criteria EPA should consider as it determines the
potential acceptability of such third-party studies."' Specifically, EPA asked
NAS to provide recommendations on whether internationally-accepted
protocols, such as the Declaration of Helsinki, 29 or the Common Rule could
be applied to develop the scientific and ethical criteria for EPA to evaluate
such studies.2 ' Although some third party studies are conducted according
to the criteria set forth in the Common Rule, EPA was particularly interested
27 See EPA Requests NAS Input, supra note 173; Letter from Stephen L. Johnson, Assistant
Administrator, Office of Prevention, Pesticides, and Toxic Substances, Environmental
Protection Agency, to Dr. Bruce Alberts, President, National Academy of Sciences (Dec. 14,
2001), available at http://www.epa.gov/epahome/headline3_121401 .htm; see also Jordan,
supra note 2, at 175.
And so in December of.. . last year... we asked the National
Academy of Sciences if they would be willing to provide us advice on the
subject. And they have, in fact, agreed to do so and we'll be convening
an[] advisory committee with composition we anticipate from some of the
same disciplines as our earlier group and will work with us and work with
each other to develop advice on how to deal with this particular category
of pesticides.
We have asked them to look at a variety of issues, not exclusively
ethical issues, although they are certainly included, but also scientific
issues, what factors should we consider in determining whether to accept
or rely on human studies performed by third parties. Are there boundaries,
clear lines that could be drawn between those studies that are acceptable,
both ethically and scientifically or studies that can be clearly put aside
because they don't meet standards of scientific and ethical acceptability.
Id.
218 EPA Requests NAS Input, supra note 173.
29 World Medical Association Declaration of Helsinki: Ethical Principles for Medical
Research Involving Human Subjects, 52d WMA Gen. Assembly Doc. 17.C (Oct. 2000), as
amended by WMA Gen. Assembly, Washington (Jun. 10, 2002) (clarifying paragraph 29),
available at http://www.wma.net/e/policy/pdf/1 7c.pdf [hereinafter Declaration ofHelsinki].
The World Medical Association Declaration of Helsinki is "a statement of ethical principles
to provide guidance to physicians and other participants in medical research involving human
subjects." Id. at para. 1.
220 Letter from Stephen L. Johnson to Dr. Bruce Alberts, supra note 217.
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in recommendations with respect to those that are not.22 ' EPA asked the NAS
to conduct an open and participatory process involving federal partners, inter-
ested parties, and the public222 as part of its policy development regarding
future acceptance, consideration, or regulatory reliance on such studies that
intentionally dose human subjects.
Similar to the earlier groups which studied this issue, the fourteen
members of NAS assigned to this project committee have expertise in many
areas of science, law, politics, ethics, medicine, and philosophy. 23 As of
January 13, 2004, this group had met ten times, and is in the process of
reviewing its draft report, findings, conclusions, and recommendations.2 4 It
had expected to release its final report in December 2003.25
221 Id.
222 Id.
2 For a list of members, see COMM. ON THE USE OF THIRD PARTY TOXICITY WITH HUMAN
RESEARCH PARTICIPANTS, NAT'L ACADEMY OF SCI., PANEL MEMBERS, at http://www7.
nationalacadernies.org/stl/Human subjectscommittee.html (last visited Jan. 12, 2004).
224 Id.
225 Human Testing; Advance Notice of Proposed Rulemaking, 68 Fed. Reg. 24,410, 24,413
(proposed May 7, 2003) (to be codified 40 C.F.R. pt. 1); see also COMM. ON THE USE OF
THIRD PARTY TOXICITY WITH HUMAN RESEARCH PARTICIPANTS, NAT'L ACADEMY OF SCI.,
THE CURRENT PROJECTS SYSTEM: USE OF THIRD PARTY TOXICITY RESEARCH WITH HUMAN
RESEARCH PARTICIPANTS (2002), athttp://www4.nas.edu/cp.nsf/0/0562bf54ed46079d85256
c2900712227?OpenDocument; COMM. ON THE USE OF THIRD PARTY TOXICITY WITH
HUMAN RESEARCH PARTICIPANTS, NAT'L ACADEMY OF SCI., THE CURRENT PROJECTS
SYSTEM: USE OF THIRD PARTY TOXICrrY RESEARCH WITH HUMAN RESEARCH PARTICIPANTS:
PROJECT SCOPE (2002), at http://www4.nas.edu/webcr.nsf/ [hereinafter COMM. ON THIRD
PARTY TOXICITY RESEARCH, PROJECT SCOPE]. The committee created within the NAS is
working with the questions presented to it by EPA. See COMM. ON THIRD PARTY TOXICITY
RESEARCH, PROJECT SCOPE, supra. EPA posed five questions to the committee. Id. These
questions were:
1) Whether and if so to what extent EPA's decision to accept, consider
or rely on a third party, human toxicity study should depend on:
a) whether the study was conducted in substantial compliance with the
provisions of the Common Rule or another standard for the
protection of human subjects;
b) the type of substance tested...;
c) whether the results of the study tend to indicate that the substance
tested is more risky or less risky than is indicated by other available
data;
d) the statistical power of the study, or the ability or inability to
measure the same endpoints in humans that have been observed in
animal testing of the same substance, or other specific charac-
teristics of the study design[;]
e) when the study was conducted in relation to the date of any state-
ment of policy by EPA regarding the ethical conduct of such
studies;
f) whether there are alternative methods of obtaining data of com-
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7. Advance Notice of Proposed Rulemaking
On May 7, 2003, EPA published an advance notice of proposed
rulemaking ("ANPR") in the Federal Register.226 This notice indicated that
the Agency plans "to conduct rulemaking about criteria and standards EPA
would apply in deciding the extent to which it will consider or rely on various
types of research with human subjects to support its actions." 227 Through this
rulemaking process, EPA states that it will consider the report expected from
NAS in December 2003, as well as comments it receives in response to the
ANPR.22 s When the public comment period closed on August 20,2003, EPA
had 194 documents in the docket, including comments from the American
Chemistry Council, Bayer CropScience, Inc., the Chemical Producers and
Distributors Association, many universities, private citizens, environmental
parable scientific merit that would not involve deliberate dosing of
human subjects;
g) the nature of the test sponsor's interest in a regulatory matter that
could be affected by consideration of the data;
h) how EPA intends to use the results in its regulatory decision making
i) whether the study has been submitted in response to a regulatory
requirement of EPA, or whether it was conducted in conformity with
an EPA Guideline;
j) EPA's assessment of the actual or potential benefits, if any, to the
individual human subjects of the research, or to society;
2) Under what circumstance(s), if any, the availability of human data
should lead EPA to consider reducing or removing the customary
tenfold interspecies uncertainty factor;
3) What existing standards... are available for evaluating the design
and the conduct of research with human subjects, and which of these
standards would be most appropriate in judging whether human
toxicity studies submitted to EPA in support ofa regulatory decision
were conducted ethically and in a way fully protective of the
interests and safety of the human subjects;
4) Whether an if so how the requirements of the Common Rule should
be extended to the conduct of third party research with human
subjects intended for submission to EPA in support of a regulatory
decision; and
5) To what extent and how the submitter of research with human
subjects to EPA should be required to document or otherwise
demonstrate compliance with appropriate standards for the pro-
tection of human research subjects?
Id.226 Human Testing; Advance Notice of Proposed Rulemaking, 68 Fed. Reg. at 24,410.
227 Id.
228 Id. at 24,414.
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organizations, and the Center for Regulatory Effectiveness. 229 EPA does not,
however, indicate whether it plans to consider all of the other information it
has requested and gathered or which is otherwise available to it, such as the
Belmont Report,230 the report ofthe joint SAB and SAP subcommittee,23' and
others.
In ANPR, EPA posed a list of detailed questions.232 The questions EPA
posed, although similar to those in its earlier charges to the joint SAB and
SAP subcommittee and NBAC, are much more specific in nature. EPA
expects that the rule it created through this process will help it: (1) determine
"whether EPA would accept, consider, or rely on results from ... studies
involving intentional dosing of human subjects," (2) "[e]stablish minimum
standards relating to the protection of human subjects.., required to be met
in the design and conduct of a study with human subjects, in order for EPA
to accept, consider, or rely on the [study] results," and (3) "[e]stablish pro-
cedures for ensuring that ... minimum standards.. . had been adhered to in
the conduct of any... study" involving human subjects "that EPA intended
to accept, consider, or rely on.
2 33
229 ENVTL. PROT. AGENCY, DOCKET ID OPP-2003-0132, HUMAN TESTING; ADVANCENOTICE
OF PROPOSED RULEMAKING (May 7, 2003), at http://cascade.epa.gov/RightSite/dk_public_
collection detail.htm?ObjectType=dkdocketcollection&cid=OPP-2003-
0132&ShowList--items&Action=view.
230 Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects
of Research, Report of the National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research, 44 Fed. Reg. 23,192-97 (Apr. 18, 1979).
23 SAB & FIFRA SAP, supra note 25.
232 In seeking comments pertaining to this rule, EPA specifically sought comments on:
1. Applicability of existing standards ....
2. Should the standard of acceptability vary depending on the re-search
design?...
3. Should the standard of acceptability vary depending on the pro-
venance of the research?...
4. Should the standard of acceptability vary depending on EPA's po-
tential use of the data?...
5. Should the standard of acceptability vary depending on EPA's as-
sessment of the risks and benefits of the research to the subjects or
to society?...
6. How should the Agency implement standards of acceptability?...
Human Testing; Advance Notice of Proposed Rulemaking, 68 Fed. Reg. 24,410, 24,414-15
(proposed May 7, 2003) (to be codified at 40 C.F.R. pt. 1) (emphasis omitted) (subsidiary
questions omitted).
Human Testing; Advance Notice of Proposed Rulemaking, 68 Fed. Reg. at 24,414.
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V. EXISTING GUIDES FOR EPA TO USE IN SETTING ITS POLICY
There are multiple existing documents which EPA could either adopt or
adapt in setting its policy regarding pesticide toxicity studies involving
human subjects. All of these models existed before EPA embarked on even
the most recent series of two-year processes culminating in reports and
recommendations, and well before EPA began its current rulemaking process
in May 2003. In this rulemaking process, EPA should consider the Common
Rule as a model. 3 EPA should also consider the historic Nuremberg Code,235
the Declaration of Helsinki, 236 the Belmont Report, 237 and existing recom-
mendations of the Office of Human Subjects at the National Institutes of
Health.238 There has even been federal legislation proposed on the subject,239
which could provide EPA additional information.
Much of the information available to EPA, although certainly not all, is
in the form of standards or guidelines originally designed to govern the con-
duct of medical or scientific research. In its May 2003 ANPR, EPA sought
comments on whether it would be "appropriate to use a standard intended to
guide the conduct of research.., to assess the acceptability for review of
completed research." 2" As examples of such existing standards of conduct,
EPA cited the Common Rule, the Nuremberg Code, and the Declaration of
Helsinki.24'
A. The Common Rule
One obvious guide for EPA to use as it creates a policy on using data
from third party pesticide toxicity studies is the Common Rule itself. As set
234 See rules cited supra note 48.
235 2 TRIALS OF WAR CRIMINALS BEFORE THE NUERNBERG MILITARY TRIBUNALS UNDER
CONTROL COUNCIL LAW NO. 10: NUERNBERG OCTOBER 1946-APRIL 1949 181-182 (U.S.
Gov't Printing Office 1949) [hereinafter NUERNBERG MILITARY TRIBUNALS].
236 Declaration of Helsinki, supra note 219.
23 7 Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects
of Research, Report of the National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research, 44 Fed. Reg. 23,192-97 (Apr. 18, 1979).
231 OFFICE OF HUMAN SUBJECTS RESEARCH, NAT'L INST. OF HEALTH, OHSR INFORMATION
SHEETS/FORMS, at http://www.nihtraining.com/ohsrsite/info/info.htmnl (last visited Sept. 11,
2003) (publishing numerous documents and forms which set forth principles EPA might
follow as guides).
239 Human Research Subject Protections Act of 2002, H.R. 4697, 107th Cong. (2d Sess.
2002). See notes 293 & 306 and accompanying text.24 0 Human Testing; Advance Notice of Proposed Rulemaking, 68 Fed. Reg. at 24,414.
241 Id.
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forth in greater depth above, the Common Rule guides all research with
human subjects conducted or supported by seventeen departments and
agencies of the United States government.242 In particular, it requires that
research involving human subjects be approved in advance by an ERB and
that subjects consent voluntarily to participate in the research.243 Consent
must be "informed consent" following explanation of the risks and benefits
of the research.24 Many agencies have adopted the Common Rule as internal
policy, some electing to apply its requirements to third-party studies. 45 The
Common Rule is the result of over fifty years of discussion of ethical
principles and guidelines for conducting research using human subjects,
beginning with the creation of the Nuremberg Code in the 1940's. "Through
these years, several international and national commissions have contributed
valuable" models and guidelines for "the protection of human research
subjects. '24 6 In its recent ANPR, EPA sought comments specifically addres-
sing whether the Agency should extend the requirements of the Common
Rule to the conduct of third party research with human subjects when that
research is intended for submission to EPA.247
B. The Nuremberg Code
Another guide EPA could use is that set forth in the Nuremberg Code.
The Nuremberg Code, originally proposed before the Nuremberg Military
Tribunals between October 1946 and April 1949, governs what data courts
can use to determine criminal culpability and to set penalties for war crim-
inals in regards to scientific studies.2 4' The criminals with which the code first
dealt were the members of the Nazi party who conducted scientific experi-
ments within concentration camps during World War 11.249
The Nuremberg Code, although originally used only for the war crimes
trials following World War II, has now been extended to apply to the general
ethical standards to which a physician must adhere. 250 Although the Nur-
242 Id. at 24,412 § (II)(A); see description of the Common Rule, supra note 1.
243 See sources supra note 1.
2
" Id.
245 See rules cited supra note 48.
246 NAT'L INST. OF JUSTICE, supra note 72.
247 Human Testing; Advance Notice of Proposed Rulemaking, 68 Fed. Reg. at 24,414.
248 NUERNBERG MILITARY TRIBUNALS, supra note 235, at 181.
249 Id.
250 See The Nuremberg Code, 313 Brit. Med. J. 1448(1), 1448(1) (1996). The Nuremberg
Code sets forth the following ten principles to determine legitimacy in scientific studies:
244 [Vol. 28:205
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1 The voluntary consent of human subjects is absolutely essential..
. This means that the person involved should have legal capacity
to give consent; should be so situated as to be able to exercise free
power of choice, without the intervention of any element of force,
fraud, deceit, duress, over-reaching, or other ulterior form of con-
straint or coercion; and should have sufficient knowledge and
comprehension of the elements of the subject matter involved as to
enable him to make an understanding and enlightened decision. This
latter element requires that before the acceptance of an affirmative
decision by the experimental subject there should be made known
to him the nature, duration, and purpose of the experiment; the
method and means by which it is to be conducted; all incon-
veniences and hazards reasonably to be expected; and the effects
upon his health or person which may possibly come from his
participation in the experiment.
The duty and responsibility for ascertaining the quality of the
consent rests upon each individual who initiates, directs or engages
in the experiment. It is a personal duty and responsibility which may
not be delegated to another with impunity.
2. The experiment should be such as to yield fruitful results for the
good of society, unprocurable by other methods or means of study,
and not random and unnecessary in nature.
3. The experiment should be so designed and based on the results of
animal experimentation and a knowledge of the natural history of
the disease or other problem under study that the anticipated results
will justify the performance of the experiment.
4. The experiment should be so conducted as to avoid all unnecessary
physical and mental suffering and injury.
5. No experiment should be conducted where there is an a priori
reason to believe that death or disabling injury will occur; except,
perhaps, in those experiments where the experimental physicians
also serve as subjects.
6. The degree of risk to be taken should never exceed that determined
by the humanitarian importance of the problem to be solved by the
experiment.
7. Proper preparations should be made and adequate facilities provided
to protect the experimental subject against even remote possibilities
of injury, disability, or death.
8. The experiment should be conducted only by scientifically qualified
persons. The highest degree of skill and care should be required
through all stages of the experiment of those who conduct or engage
in the experiment.
9. During the course of the experiment the human subject should be at
liberty to bring the experiment to an end if he has reached the
physical or mental state where continuation of the experiment seems
to him to be impossible.
10. During the course of the experiment the scientist in charge must be
prepared to terminate the experiment at any stage, if he has probably
[sic] cause to believe, in the exercise of the good faith, superior skill
and careful judgment required of him that a continuation of the
experiment is likely to result in injury, disability, or death to the
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emberg Code was created to protect human prisoners from non-consensual
and dangerous medical research, its principles have been adopted and adapted
into many related contexts, including the Common Rule. In its latest ANPR,
EPA cited the Nuremberg Code as an example of an existing standard of
conduct for research involving human subjects, and sought comments on
whether such standards should be used to assess the acceptability for review
of research that has already been completed.25'
C. The Declaration of Helsinki
Like the Common Rule and the Nuremberg Code, the Declaration of
Helsinki ("the Declaration") 25 2 could serve as a guide to the creation of an
EPA policy governing data from third party pesticide toxicity studies
involving human subjects. The Declaration, first adopted by the World
Medical Association in 1964, sets forth ethical principles which guide
physicians and other researchers using human subjects, and "apply to research
on matters relating to the diagnosis and treatment of human disease .... ,253
The Declaration states that the "primary purpose of medical research
involving human subjects is to improve prophylactic, diagnostic, and thera-
peutic procedures and the understanding of aetiology and pathogenesis of
disease. '254 "In medical research on human subjects, considerations related
to the well-being of the human subject should take precedence over the
interests of science and society. ' 255 Like other research guidelines, the
Declaration states that "[i]t is the duty of the physician in medical research
to protect the life, health, privacy, and dignity of the human subject." '256
Furthermore, the Declaration lays out a series of "basic principles," which
include:
The design and performance of each experimental
procedure involving human subjects should be clearly
experimental subject.
NUERNBERG MILITARY TRIBUNALS, supra note 235, at 181-82.
25 Human Testing; Advance Notice of Proposed Rulemaking, 68 Fed. Reg. at 24,414.
252 See Declaration of Helsinki, supra note 219.
253 Human Testing; Advance Notice of Proposed Rulemaking, 68 Fed. Reg. at 24,412; see
Declaration of Helsinki, supra note 219.
254 Declaration of Helsinki, supra note 219, at para. 6.
255 Id. at para. 5.
25 Id. at para. 10.
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formulated in an experimental protocol. This protocol
should be submitted... [to and approved by an inde-
pendent] ethical review committee ....
The research protocol should.., contain a statement of
the ethical considerations involved ....
Medical research involving human subjects should be
conducted only by scientifically [and medically] quali-
fied persons ....
Every medical research project involving human sub-
jects should be preceded by careful assessment of
predictable risks and burdens in comparison with
foreseeable benefits to the subject or to others....
Physicians should abstain from engaging in research
projects involving human subjects unless they are con-
fident that the risks involved have been adequately
assessed and can be satisfactorily managed....
Medical research is only justified if there is a reasonable
likelihood that the populations in which the research is
carried out stand to benefit from the results of the
research.
The subjects must be volunteers and informed partici-
pants in the research project.
The right of research subjects to safeguard their integrity
must always be respected....
In any research on human beings, each potential subject
must be adequately informed of the aims, methods,
sources of funding, any possible conflicts of interest,
institutional affiliations of the researcher, the anticipated
benefits and potential risks of the study and the dis-
comfort it may entail. The subject should be informed of
the right to abstain from participation in the study or to
withdraw consent to participate at any time without re-
prisal. After ensuring that the subject has understood the
information, the physician should then obtain the
subject's freely-given informed consent, preferably in
writing. If the consent cannot be obtained in writing, the
non-written consent must be formally documented and
witnessed.
2472004]
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" When obtaining informed consent for the research
project the physician should be particularly cautious if
the subject is in a dependent relationship with the phy-
sician or may consent under duress....
* For a research subject who is legally incompetent...
[or] incapable of giving consent . . . the investigator
must obtain informed consent from the.. . authorized
representative in accordance with applicable law. These
groups should not be included in research unless the
research is necessary to promote the health of the popu-
lation represented and.., cannot ... be performed on
legally competent persons.
* When a subject deemed legally incompetent ... is able
to give assent to decisions about participation in re-
search, the investigator must obtain that assent in
addition to the consent of the legally authorized
representative.
* Research on individuals from whom it is not possible to
obtain consent.., should be done only if the physical/
mental condition that prevents obtaining informed
consent is a necessary characteristic of the research
population....
* Both authors and publishers have ethical obligations....
Reports of experimentation not in accordance with the
principles laid down in this Declaration should not be
accepted for publication."'
The standards also apply to research that adds to the understanding of the
causes of disease and the relationships between biological mechanisms that
explain the relationships between human exposures to environmental agents
and disease.258 Although neither identical to the Common Rule nor directly
applicable to EPA's current struggle, the Declaration of Helsinki is similar
in important ways to the Common Rule. For example, in both the Declaration
of Helsinki and the Common Rule, the individuals conducting testing on
human subjects must inform the research subjects of the risks of being sub-
... For the full text of the Declaration's basic principles, see id. at paras. 13-27.
25 Human Testing; Advanced Notice of Proposed Rulemaking, 68 Fed. Reg. at 24,412.
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jects of the study." 9 Both guides require that the subject have the option to
end participation in the study at any point.26 Both guides set forth a process
for reviewing and approving research protocols.2 ' The Declaration of
Helsinki and the Common Rule require that the studies be approved by
boards of experts that are unrelated to either the parties conducting the studies
or the agencies, or industry for whom the study is being conducted.262 In both
guides, these boards must weigh the benefits that will be advanced upon
society by the study against the risks and consequences that the study may
have on the individuals who participate in it when evaluating studies. 63
Although the Common Rule has standards that researchers must follow, the
Declaration of Helsinki's are more stringent. The Declaration provides more
specific guidance regarding the standards required for research on groups
such as the elderly and young children.26 This information is used by review
boards in determining whether the testing will be more harmful to the
individuals than helpful to society.265
Interestingly, the most recent version of the Declaration, with amend-
ments adopted in 2000, differs from previous versions in ways that are appli-
cable to EPA's current dilemma. For instance, up through the 1996 version,
the Declaration said that
[i]n the field of biomedical research, a fundamental dis-
tinction must be recognized between medical research in
which the aim is essentially diagnostic or therapeutic for a
patient, and medical research, the essential object of which is
purely scientific and without implying direct diagnostic or
therapeutic value to the person subjected to the research.2 66
Although it would be difficult to argue that research on human subjects the
object of which is to encourage EPA to set a lower NOAEL is medical
259 See 40 C.F.R. § 26.116; Declaration of Helsinki, supra note 219, at paras. 20, 22-23.
'60 See 40 C.F.R. § 26.116(b)(4); Declaration of Helsinki, supra note 219, at para. 22.
261 See 40 C.F.R. § 26.109; Declaration of Helsinki, supra note 219, at para. 13.
262 See 40 C.F.R. § 26.107; Declaration of Helsinki, supra note 219, at para. 13.
263 See 40 C.F.R. §§ 26.109, 26.111; Declaration of Helsinki, supra note 219, at para. 17.
264 See Declaration of Helsinki, supra note 219, at paras. 24-26.
265 See 40 C.F.R. § 26.109; Declaration of Helsinki, supra note 219, at para. 13.
266 World Medical Association Declaration of Helsinki: Ethical Principles for Medical
Research Involving Human Subjects, 48th WMA Gen. Assembly Doc. 17.C (1996), amended
by Declaration of Helsinki, supra note 219, available at http://www.med.uni-heidelberg.de/
kks-hd/Links/DeklarationHelsinki 1 996.pdf.
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research at all, such research is certainly not essentially diagnostic or thera-
peutic. This reference, which highlights a distinction between research that
helps the individual human subject and research that has another purpose, is
no longer in the 2000 Declaration.2 67 Although the World Medical Associ-
ation has removed this language from its Declaration, EPA could maintain
this distinction as recommended by thejoint SAB and SAP subcommittee.268
If EPA follows the advice of the joint SAB and SAP subcommittee, it
would create a policy that focuses on the risks and benefits to the individual
human research subject, like the earlier version of the Declaration of
Helsinki. EPA could choose to reject research that is not designed to be diag-
nostic or therapeutic, as in the case of pesticide toxicity studies designed to
influence the Agency's tolerance decisions.
In the second applicable point, the Declaration assigns some respon-
sibility for the ethical nature of medical research to parties other than the
researchers themselves. 26 9 For example, the Declaration states that reports of
experimentation not conducted in accordance with the principles in the
Declaration should not be accepted for publication.27 This places respon-
sibility for the ethical nature of studies not only on the researchers them-
selves, but also on the journals that publish medical research. EPA's policy
could follow this example by placing responsibility for the ethical nature of
studies on itself as well as on third party researchers. EPA could set a policy
in which it, like the publishers referenced in the Declaration, would not
accept data from research not governed by a strong ethical standard, like the
Common Rule.
EPA is clearly considering what the Declaration might have to offer with
respect to its policy needs. In its recent ANPR, EPA raises the question
whether the Declaration, "a standard intended to guide the conduct of
therapeutic or diagnostic medical research or to clarify causes of disease,"
would be appropriate "to assess the acceptability for review of other kinds of
research without diagnostic or therapeutic intent, conducted with healthy
subjects. 271' Also, EPA asks whether it would be appropriate for it to "apply
a standard maintained by a private, non-governmental organization," such as
the World Medical Association, to its own process of assessing the accept-
ability of research conducted on human subjects.272
267 Compare id. with Declaration of Helsinki, supra note 219, paras. 4-5.
21S See SAB & FIFRA SAP, supra note 25, at 38.
269 Declaration of Helsinki, supra note 219, para. 27.
270 id.
271' Human Testing; Advance Notice of Proposed Rulemaking, 68 Fed. Reg. at 24,414.
272 id.
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D. The Belmont Report
In 1979, the Department of Health, Education, and Welfare, published
the Belmont Report: Ethical Principles and Guidelinesfor the Protection of
Human Subjects of Research.273 This report should serve as an additional
guide to EPA as it fashions its own policy. In the Belmont Report, the Na-
tional Commission for the Protection of Human Subjects of Biomedical and
Behavioral Research summarized what it determined to be the basic ethical
principles applicable to such research. 74 The first basic ethical principle is
respect for persons.275 This includes the notions that individuals should be
treated as "autonomous agents," and that "persons with diminished autonomy
are entitled to protection. 27 6 The second principle is beneficence. 277 This
means that the researcher should do no harm, and should maximize the
possible benefits while minimizing the possible harms. 278 Finally, the third
basic ethical principle is justice. 279 This principle refers to fairness, or what
is deserved, with respect to the distribution of benefits and burdens.8
The Belmont Report also indicates areas in which the stated ethical
principles apply.28' The first is informed consent.2 2 The report indicates that
"[r]espect for persons requires that subjects ... be given the opportunity to
choose what shall or shall not happen to them.2 83 The report discusses in
some depth the required components of informed consent-information, 84
comprehension, 285 and voluntariness. 2 6 The second application of the ethical
"' Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects
of Research, Report of the National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research, 44 Fed. Reg. 23,192-97 (Apr. 18, 1979)274 Id. at 23,192.
275 Id. at 23,193-94.276 Id. at 23,193.
277 1d. at 23,194.
278 Id.
279 The Belmont Report, 44 Fed. Reg. at 23,194.
280 Id.
211 Id. at 23,194-95.
282 Id. at 23,195.
283 Id.
28 Id. Depending on the applicable code of research, information necessary for informed
consent may include items such as; "the research procedure, their purposes, risks and
anticipated benefits, alternative procedures (where therapy is involved), and a statement
offering the subject the opportunity to ask questions and to withdraw at any time from the
research." Id.
215 The Belmont Report, 44 Fed. Reg. at 23,195. Comprehension necessary for informed
consent is a complex problem. Because subjects' abilities to understand research protocols
and risks will vary, respect for human subjects requires that researchers present information
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principles lies in the assessment of risks and benefits.2 87 This requires an
evaluation of the nature and scope of the risks and benefits, and a systematic
assessment of those risks and benefits. 88 Finally, the ethical principles,
especially the principle ofjustice, applies in the selection of subjects.289
The ethical principles and applications of those principles set forth in
1979 in the Belmont Report, although simple, could serve as a base model for
EPA as it creates a policy for how it should view data from third-party
pesticide toxicity studies involving human subjects. These principles, and
their applications, although written with medical research in mind, would
apply similarly to pesticide toxicity research and other human subjects
research submitted to EPA.
VI. EXISTING PROPOSAL FOR FEDERAL LEGISLATION
In addition to the already existing models set forth above, legislators
have suggested another answer to the problem of third-party pesticide toxicity
studies on human subjects. Legislators and regulators have attempted to
create laws and regulations on this subject at both the federal and state
levels.29 On May 9, 2002, Representatives Diana DeGette (D-Colo.) and
in a manner in which the subject is likely to understand it. Id. Without comprehension of the
necessary information regarding the research, there can be no informed consent. Id.
.d. at 23,195. For informed consent to be voluntary, it must be "free of coercion and undue
influence." Id.
"
7 Id. at 23,195-96.
288 Id. at 23,196.
1S9 Id. at 23,196-97.
2
90 See, e.g., CAL. CODE REGS. tit. 3, § 6710 (2003). In this new regulation, effective April
24,2003, the California Department of Pesticide Regulations ("DPR") alters the method "by
which DPR approves scientific protocols from an ethical and technical perspective for
California-based pesticide exposure studies that involve human" subjects. This regulation
concerns pesticide exposure studies, in which researchers collect data regarding agricultural
workers' exposure to pesticides during their work. Id. This type of study, which provides
valuable, reliable, and accurate exposure for risk assessment, is qualitatively and ethically
different from those studies that intentionally doses human subjects with pesticides. Id.
However, the existence of this new rule in California shows that agencies are grappling with
ethical concerns regarding human participants in pesticide studies. It further indicates that
when grappling with the issue, the California DPR chose to impose the strictures of the
federal Common Rule, and did not distinguish between studies to which the Common Rule
would otherwise apply, and those to which it would not otherwise apply. Id.
The purpose of these pesticide exposure studies is to find new means to evaluate the
risks of pesticide exposure, and prevent overexposure to pesticides. Id. The previous law in
California require(d) that "no person shall conduct any pesticide exposure study in [the state],
which involves human participants, unless the DPR Director has given written approval of
the protocol." Id. The previous law required that the state's Office of Environmental Health
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James Greenwood (R-Pa.) introduced legislation in the United States Con-
gress designed to ensure protection of human research subjects, specifically
including those who participate in pesticide toxicity research. 291 The bill, the
Human Research Subject Protections Act of 2002, would amend the Public
Health Service Act 292 to apply the Common Rule to all research involving
human subjects, notjust to research funded by the federal government. 293 The
bill also proposes to codify a plan that would reduce the strain on IRBs that
oversee the scientific integrity and ethics of much human-based research.294
The bill intends to cover all studies involving human participants, regardless
whether the studies were conducted in circumstances already covered by the
Common Rule.295 The bill is intended specifically to address EPA's current
dilemma; studies not currently subject to the Common Rule because they are
not conducted or funded by a federal agency.296 The bill, like the Common
Rule itself, would require researchers to inform human participants about the
risks of the study.297 It would also require the participant to provide informed
consent after receiving this information. 29' The bill would require both
and Hazard Assessment review the protocol. Id. That office reviewed the studies' protocols
from an ethical perspective, and also provided technical guidance on the conduct of the study
as well. Id. The previous law indicated that the items included in a protocol for this type of
study were similar to the requirements of the Common Rule. Id. It required "pesticide
labeling directions and rates to be used, proposed starting and completion dates of the study,
background and justification for the study, study design, methods to be used, selection
process for human participants, criteria for exclusion or inclusion of participants, written
consent, medical supervision, and compensation." Id. Finally, previous law also required that
DPR submit the protocols "to an appropriate committee of a public or private California
research university." Id. Until recently, that function was performed by the University of
California at San Francsico ("UCSF") under contract with DPR. Id. As the costs of
performing the protocol reviews increased for the university, the university requested
increased funding to cover those costs. Id. DPR could not allocate additional funding,
however, and UCSF declined to perform further reviews. Id. at 2284. DPR has been unable
to contract any other university to perform the protocol reviews, as required by statute. Id.
at 2284. Therefore, DPR had to revise its protocol review requirements. The new regulation
is that revision. It requires the director of a pesticide exposure study involving human
subjects to obtain an Institutional Review Board ("IRB") to conduct the ethical review of
California pesticide study involving human subjects. Id. DPR accepts the IRB's review,
provided it meets the requirements of the Common Rule. Id.
" Human Research Subject Protection Act of 2002, H.R. 4697, 107th Cong. (2d Sess.
2002); Phibbs, supra note 31, at A-3.
292 42 U.S.C. § 289 (2000).
293 Phibbs, supra note 31, at A-4.
294 See id.; see also supra note 290 (regarding the difficulties with IRB funding in California).
293 Phibbs, supra note 3 1, at A-4.
296 Id.297 Id.
298Id.
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researchers and members of IRBs to disclose conflicts of interest that might
affect the study.
2 99
The bill would provide that the Office of Human Research Protection,
housed in the United States Department of Health and Human Services, be
responsible for enforcement."' Despite the lack of any provisions for civil
penalties, the bill would authorize the Human Research Protection Office to
stop studies that fail to comply with the requirements.30 ' In addition, that
office could prohibit any agency, institution, or company from conducting
human subject research.30 2
The bill was referred to the House Energy and Commerce Committee,
in which Representative Greenwood is Chair of the Oversight and Investi-
gations Subcommittee.3 3 To date, it has received no further action.3°
VII. CONCLUSION
Congress' passage of FQPA in cooperation with then-existing pesticide
registration and food safety laws, created legal circumstances that encourage
pesticide manufacturers to conduct pesticide toxicity research on human
subjects. FQPA required EPA to reassess the toxicity of pesticides it had
already registered, as well as to examine new pesticides seeking registration,
to determine their tolerances-how much of that pesticide could remain on
food before the food would be declared adulterated. Existing law required
EPA to impose a tenfold multiplier to the amount of pesticide exposure at
which there is no observable adverse effect, to determine a reference
dose-the amount of that pesticide a human being could ingest daily, for
seventy years, without observed effect. One original multiplier, the inter-
species uncertainty factor, accounted for the uncertainty that arises in using
data from animal studies when setting pesticide tolerances for humans. FQPA
required EPA to impose an additional tenfold multiplier to protect human
children. In setting reference doses, and therefore tolerances, neither EPA,
nor pesticide manufacturers, could avoid the tenfold factor for the protection
299 Id.
300 id.
301 Phibbs, supra note 31, at A-4.
302 Id.
103 Id. at A-3.
31 See THOMAS LEGISLATIVE INFO., LIBRARY OF CONG., BILL SUMMARY & STATUS FOR THE
107TH CONGRESS: H.R. 4697, at http://thomas.loc.gov/ (last visited Oct. 22, 2003).
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of human children. With an increased use of human subject testing, however,
they could avoid or reduce the tenfold interspecies uncertainty factor.
Pesticides manufacturers, therefore, could get higher reference doses and
tolerances by using human subject research to avoid or reduce the inter-
species uncertainty factor.
Although human subject research conducted with EPA's approval is
subject to the Common Rule, third party studies do not face the same
protective constraints. Therefore, for example, Common Rule studies must
be approved by an IR before they begin; the researchers must ensure that
subjects understand the studies' risks, and with that understanding, the sub-
jects must commit voluntarily to participate; and the researchers must ensure
privacy for the subjects. Although FIFRA requires that human subjects of
pesticides research provide informed consent, studies conducted by pesticide
manufacturers are not otherwise required to protect human subjects in any of
these ways.
EPA knew since the Nixon administration, although more pointedly
since the publication of The English Patients in 1998, that it needs to estab-
lish a policy regarding data from human studies conducted or submitted by
pesticide manufacturers. On the one hand, these studies could provide useful
information on pesticide toxicity. On the other hand, encouraging human
subj ect pesticide research would mean intentionally dosing many people with
substances designed to kill living beings, with no possible direct benefit to
the individual subjects themselves.
EPA sought and received specific advice on this subject from the
National Bioethics Advisory Commission, and from ajoint subcommittee of
its own SAB and SAP. Each of these entities heard testimony and advice
from a wide variety of experts, and submitted a report or recommendations
to EPA. EPA has sent the problem out yet again, for another two-year
process, to NAS. The NAS committee has heard testimony from another
diverse group of experts, most in disciplines from which testimony was
already received in earlier iterations of this process. It was supposed to issue
a report to EPA in December 2003. Presumably, one is forthcoming shortly.
In addition to the reports that have been the products of these several
two-year processes, EPA has other information at its disposal, which, if the
Agency follows through on its recent Advance Notice of Proposed Rule-
making, it should consider. In forming a policy regarding data from third
party pesticide toxicity studies, EPA could adopt the Common Rule itself,
one of several existing codes of ethics and guidelines for practice in human
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subjects research, or use the guidance those provide to create its own
requirements. It could also use the ideas and principles set forth in the
Nuremberg Code, the Declaration of Helsinki, the National Institutes of
Health guidelines, or even proposed federal legislation.
Rather than continuing to postpone the issuance of a policy by seeking
additional multi-year processes, EPA should evaluate the information before
it and establish a clear policy for protecting human subjects in third party
pesticide toxicity studies. Existing guidelines and policies are largely con-
sistent. Like the Common Rule, these guidelines and policies generally
require that subjects understand the risks of the study and agree voluntarily
to participate. They require independent review and approval of the research
prior to its commencement, and they require privacy for the subjects.
With respect to pesticide toxicity studies, the most controversial
problem EPA must face is whether it should accept data from human subjects
studies gathered for the purpose of setting higher reference doses and
tolerances, the fundamental purpose of which would be to sell more
pesticides. The joint SAB and SAP subcommittee raised this question and
suggested that it should not. The joint SAB and SAP subcommittee asserted
that the intent or purpose of human subject research matters. Although all
groups which studied this issue agreed that human studies can provide
valuable information regarding pesticide toxicity, the joint SAB and SAP
subcommittee is the only group that dealt with the intent of the study and
suggested that EPA should not accept data from human third party pesticide
toxicity studies that have the sole purpose of increasing reference doses, and
thereby tolerances, in order to sell more pesticides.
Armed with the many existing codes of ethics and guidelines for human
subject research, and with the additional suggestions of the joint SAB and
SAP subcommittee regarding the intent and purpose of human subject
research, EPA should be able to determine a policy. This policy should allow
the Agency to gather the information it needs to set protective reference doses
and tolerances according to requirements of the statutes, while protecting
human research subjects consistent with existing guidelines and codes of
ethics.
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